0001104659-23-054557.txt : 20230501 0001104659-23-054557.hdr.sgml : 20230501 20230501172359 ACCESSION NUMBER: 0001104659-23-054557 CONFORMED SUBMISSION TYPE: 10-K/A PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230501 DATE AS OF CHANGE: 20230501 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NRX Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001719406 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 822844431 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38302 FILM NUMBER: 23875304 BUSINESS ADDRESS: STREET 1: 1201 ORANGE STREET STREET 2: SUITE 600 CITY: WILMINGTON STATE: DE ZIP: 19801 BUSINESS PHONE: 484-254-6134 MAIL ADDRESS: STREET 1: 1201 ORANGE STREET STREET 2: SUITE 600 CITY: WILMINGTON STATE: DE ZIP: 19801 FORMER COMPANY: FORMER CONFORMED NAME: Big Rock Partners Acquisition Corp. DATE OF NAME CHANGE: 20171012 10-K/A 1 tm2314196d1_10ka.htm FORM 10-K/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-K/A

(Amendment No. 1)

(Mark One)

x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Fiscal Year Ended: December 31, 2022

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-38302

NRX PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware		82-2844431
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

1201 Orange Street, Suite 600

Wilmington, DE 19801

(Address of principal executive offices) (Zip Code)

(484) 254-6134

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:	Trading Symbol(s)	Name of each exchange on which registered:
Common Stock, par value $0.001 per share	NRXP	The Nasdaq Stock Market LLC
Warrants to purchase one share of Common Stock	NRXPW	The Nasdaq Stock Market LLC

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes ¨ No x

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

Yes ¨ No x

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ¨	Accelerated filer ¨
Non-accelerated filer x	Smaller reporting company x Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ¨

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ¨

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

The aggregate market value of common stock held by non-affiliates of the registrant based on the closing price of the registrant’s common stock as reported on the Nasdaq Global Select Market on June 30, 2022, was $40,584,788.4 million.

As of April 27, 2023, the registrant had 71,557,580 shares of common stock outstanding.

PCAOB Auditor ID: 185

Name : KPMG LLP

Address: Short Hills, new Jersey

EXPLANATORY NOTE

NRx Pharmaceuticals, Inc. (the “Company”) is filing this Amendment No. 1 (this “Form 10-K/A”) to its Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2023 (the “Form 10-K”), for the purpose of including the information required by Part III and Exhibits required by Part IV of Form 10-K.

As required by Rule 12b-15, in connection with this Form 10-K/A, the Company’s Principal Executive Officer and Principal Financial Officer are providing Rule 13a-14(a) certifications included herein. Because no financial statements have been included in this Form 10-K/A and this Form 10-K/A does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications have been omitted. Because no financial statements are contained within this Form 10-K/A, the Company is not including certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Except as explicitly set forth herein, this Form 10-K/A does not purport to modify or update the disclosures in, or exhibits to original Form 10-K, or to update the original Form 10-K to reflect events occurring after the date of such filing.

INDEX

Annual Report on Form 10-K

Table of Contents

Page

Part III	1
Item 10. Directors, Executive Officers, and Corporate Governance	1
Item 11. Executive Compensation	6
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	21
Item 13. Certain Relationships and Related Transactions, and Director Independence	23
Item 14. Principal Accountant Fees and Services	24
Part IV.	25
Item 15. Exhibits, Financial Statement Schedules	25

Part III

Item 10. Directors, Executive Officers, and Corporate Governance

MANAGEMENT

The following table sets forth, as of the date of this Form 10-K/A, certain information regarding our executive officers and directors who are responsible for overseeing the management of our business.

Name	Age	Position
Executive Officers and Directors:

Stephen H. Willard	62	Chief Executive Officer, Director

Robert Besthof¹	57	Head of Operations and Chief Commercial Officer

Riccardo Panicucci	62	CMC and Technical Operations Advisor

Seth Van Voorhees	62	Chief Financial Officer

Patrick J. Flynn	74	Director

Sharon A. Glied, Ph.D.	62	Director

Aaron Gorovitz	64	Director

Chaim Hurvitz	62	Director

Jonathan Javitt, M.D., M.P.H.	66	Director, Chief Scientist

Executive Officer and Director Biographies

Stephen H. Willard. Mr. Willard has served as our Chief Executive Officer and as a member of the Board since July 2022. From 2012 to March 2021, Mr. Willard served, and since July 2022 has served, as a Director of Nozin, Inc., an infection prevention company and pioneer in nasal decolonization. From March 2021 to July 2022, Mr. Willard served as Executive Director of Nozin, Inc. From November 2013 to March 2021, Mr. Willard served as CEO of Cellphire Inc., (“Cellphire”) a leading company in platelet and cell stabilization, between, during which period he aided in the expansion of Cellphire, managed all aspects of its dynamic growth and oversaw all its operations. Prior to joining Cellphire, from 2000 to 2013, Mr. Willard served in executive roles at Flamel Technologies S.A (FLML), a drug delivery company. From 2000 to 2005, Mr. Willard served as CFO of Flamel and, from 2006 to 2013, Mr. Willard served as CEO of Flamel. From 2000 to 2014, Mr. Willard was also a member of the board of directors for E*TRADE Financial, a subsidiary of Morgan Stanley, which offers an electronic trading platform to trade financial assets. Mr. Willard has more than 20 years of experience as the CEO of pharma and biotech companies. He also has additional experience covering all aspects of building and running public and private companies, including acquisition and divestment, development, staffing, manufacturing, licensing and supply. Since 2018, Mr. Willard has served as a member of the National Science Board, which governs the National Science Foundation. Mr. Willard received a B.A. from Williams College in 1982 and a J.D. from Yale Law School in 1985.

Robert Besthof has resigned from the company and his last day with the Company is May 1, 2023.

Robert Besthof MIM. Mr. Besthof has been our Head of Operations and Chief Commercial Officer since May 2021, except from March 2022 to July 2022 where he served as our Interim Chief Executive Officer. Mr. Besthof also served as the Chief Commercial Officer of NeuroRx, Inc., the predecessor to our company, from March 2016 to May 2021. Mr. Besthof is a seasoned professional with more than 25 years of experience in biopharma marketing and operations, including at Pfizer, Wyeth, and Eli Lilly. Mr. Besthof has held various positions at Pfizer since 2004, including his most recent role as Vice President of Global Commercial Development for Neuroscience and Pain products at Pfizer. He has a track record of leadership in positions of increasing responsibility, including: profit and loss for marketing and sales and has enabled the rapid growth of pharmaceutical pipelines and led product launches across multiple therapeutic areas. Prior to joining the pharmaceutical industry, Mr. Besthof worked for Deutsche Bank and in consulting. He holds a B.A. in Economics from Case Western Reserve University, and a Masters of International Management from The Thunderbird School of Global Management

Riccardo Panicucci. Mr. Panicucci has served as our CMC and Technical Operations Advisor since January 2021. Rick is currently the SVP of CMC at BridgeBio Pharma and has served in this role since March 2018. Prior to joining BridgeBio, Mr. Panicucci served as VP of Pharmaceutical Development Services at WuXi STA from February 2015 to March 2018, where he provided scientific leadership in formulation development and GMP manufacturing. From 2004 to 2015, Mr. Panicucci served as Global Head of Chemical and Pharmaceutical Profiling (CPP) at Novartis. Mr. Panicucci has also led R&D groups at Vertex Pharmaceuticals, Symbollon Pharmaceuticals, Biogen, and Bausch & Lomb. Mr. Panicucci earned a Ph.D. in Chemistry from the University of Toronto and did a Post-Doctoral Fellowship at the University of California, Santa Barbara.

Seth Van Voorhees, Ph.D. Dr. Van Voorhees has served as our Chief Financial Officer since June 2022. Dr. Van Voorhees most recently served as CFO of PDS Biotechnology Corporation (“PDS Biotechnology”) during which he completed several financing transactions in 2021. Prior to joining PDS Biotechnology, he spent 10 years as the CFO and Vice President of Business Development for Research Frontiers Inc. from January 2010 to December 2020. Prior to this role, Dr. Van Voorhees served as CFO for American Pacific Corp. Earlier in his career, Dr. Van Voorhees was an investment banking officer responsible for chemical and pharmaceutical clients at Merrill Lynch, UBS Warburg, and Wasserstein Perella. Dr. Van Voorhees received a Ph.D. in chemistry from the University of Pennsylvania and an MBA from Columbia University.

Patrick J. Flynn. Mr. Flynn has served as a member of our Board since May 2021. Mr. Flynn is an entrepreneur with more than 35 years of senior executive experience. He has provided leadership to numerous successful organizations including start-ups and growth-stage companies and has served in a variety of roles, including Executive Chairman, board member, CEO, COO, CFO and advisor. Mr. Flynn served as a member of the NeuroRx, Inc., the predecessor of the Company, board of directors from 2017. Since 2012, Mr. Flynn has been serving as a member of the board of directors for Common Sensing Inc., a data-driven hardware and software solutions company. Additionally, Mr. Flynn currently serves as the COO of Good Measures where he is responsible for the day-to-day operations of the company’s innovative approach to healthcare and nutrition services. Prior to joining Good Measures, Mr. Flynn was the co-founder of Predilytics, Inc. and served as Executive Chairman. Before joining Predilytics, Mr. Flynn contributed his expertise as COO and then as CEO to Health Dialog, where he helped build the business from an early-stage healthcare services organization to one of the world’s leading providers of healthcare analytics, healthcare services and decision support. Prior to this role, Flynn was a co-founder of Symmetrix, a management consulting firm specializing in healthcare and financial services. Mr. Flynn began his career with Bank of America where he held several positions over the course of 15 years, including Vice President of World Banking and Vice President of Risk Management. Mr. Flynn earned his B.S. in Finance from the Wharton School at the University of Pennsylvania.

Sharon A. Glied, Ph.D. Dr. Glied has served as a member of our Board since May 2021. Dr. Glied served as a member of NeuroRx, Inc., the predecessor to our company’s board of directors from December 2015. Dr. Glied has served as the Dean of New York University’s Robert F. Wagner Graduate School of Public Service since August 2013. From 1989 to August 2013, Dr. Glied was the Professor of Health Policy and Management at Columbia University’s Mailman School of Public Health, where she served as the Chair of the Department of Health Policy and Management from 1998 to 2009. In June 2010, Dr. Glied was confirmed by the U.S. Senate as Assistant Secretary for Planning and Evaluation at the Department of Health and Human Services, serving in that capacity from July 2010 through August 2012. She has previously also served as Assistant Secretary of Health under President Obama and as a member of the President’s Council of Economic Advisors under President Bush. She is one of the world’s leading experts on mental health policy. She has been elected to the Institute of Medicine of the National Academy of Sciences, the National Academy of Social Insurance, and the Board of Academy Health, and has been a member of the Congressional Budget Office’s Panel of Health Advisers and a research associate of the National Bureau of Economic Research. She is co-editor, with Peter C. Smith, of The Oxford Handbook of Health Economics, which was published by the Oxford University Press in 2011. Dr. Glied holds a B.A. in Economics from Yale University, a Master’s degree in Economics from the University of Toronto and a Ph.D. in Economics from Harvard University.

Aaron Gorovitz. Mr. Gorovitz has served as a member of our Board since May 2021. Mr. Gorovitz served as a member of the NeuroRx, Inc., the predecessor to our company, board of directors from 2016. He is a partner of the AHG Group. In addition to his 25 years of legal experience in complex commercial transactions, he has considerable involvement in early-stage biotechnology and health information technology companies. Mr. Gorovitz holds a B.A. from Muhlenberg College and a J.D. from George Washington University Law School.

Chaim Hurvitz. Mr. Hurvitz has served as a member of our Board since May 2021. He served as a member of the NeuroRx, Inc., the predecessor to our company, board of directors from May 2015. Mr. Hurvitz has served as the Chief Executive Officer of CH Health, a private venture capital firm, since May 2011. Mr. Hurvitz previously served as a member of the board of directors of Teva Pharmaceuticals Industries Ltd. from October 2010 to July 2014. Previously, he was a member of the senior management of Teva Pharmaceuticals Industries Ltd., serving as the President of Teva International Group from 2002 until 2010, as President and Chief Executive Officer of Teva Pharmaceuticals Europe from 1992 to 1999 and as Vice President - Israeli Pharmaceutical Sales from 1999 until 2002. Mr. Hurvitz is a founding investor and a director of Galmed Pharmaceuticals Ltd. Mr. Hurvitz presently serves as a member of the management of the Manufacturers Association of Israel and head of its pharmaceutical branch. Mr. Hurvitz holds a B.A. from Tel Aviv University.

Jonathan Javitt, M.D., M.P.H. Dr. Javitt served as our Chief Executive Officer and Chairman of our Board from May 2021 until March 2022, and since March 2022, has served as Chief Scientist and as a member of our Board. He served as Chairman of the Board and the Chief Executive Officer of NeuroRx, Inc., the predecessor to our company, from its founding in 2015. Prior to starting NeuroRx, Inc., he participated in leading drug and medical device development and commercialization projects for Allergan, Alcon, Eyetech, Merck, Novartis, Pfizer, and Pharmacia. He has played leadership roles in seven successful healthcare IT and biopharma start-up companies. He was appointed to healthcare leadership roles under President Ronald Reagan, George H.W. Bush, Clinton and George W. Bush. During the Reagan and Bush ‘41 administrations, he was designated as an Expert Consultant to the Department of Health and Human Services. President Clinton designated him as a Special Government Employee of the White House Executive Office of the President to serve on the 1993 Health Reform Task Force. Under President George W. Bush, he was commissioned to lead the Healthcare Committee of the President’s Information Technology Advisory Committee and to serve as a Special Employee of the Undersecretary of Defense. Dr. Javitt has published more than 200 scientific works in the areas of health outcomes and pharmacoeconomics that have been cited more than 31,000 times. Dr. Javitt holds an A.B. with Honors from Princeton University, an M.D. from Cornell University and a Masters of Public Health from the Harvard Chan School of Public Health. In 2015, he was designated an Alumnus of Merit, the highest honor bestowed by Harvard University to graduates of the School of Public Health. He continues to serve as an adjunct Professor of Ophthalmology at Johns Hopkins School of Medicine and as a Senior Fellow of the Potomac Institute for Policy Studies.

Board Composition and Election of Directors

Director Independence

Our Board has determined that Sharon A. Glied, Patrick J. Flynn, Aaron Gorovitz, and Chaim Hurvitz are “independent directors” as defined in the Nasdaq listing standards and applicable SEC rules.

Classified Board of Directors

In accordance with our Charter, our Board is divided into three classes with staggered, three year terms. At each annual meeting of stockholders, the successors to directors whose terms then expire are elected to serve from the time of election and qualification until the third annual meeting following election. Our directors are divided among the three classes as follows:

the Class I director is Chaim Hurvitz, and his term expires at our 2025 annual meeting of stockholders;

the Class II directors are Sharon Glied and Aaron Gorovitz, and their terms will expire at our 2023 annual meeting of stockholders; and

the Class III directors are Stephen Willard, Patrick Flynn and Jonathan Javitt, and their terms will expire at the 2024 annual meeting of stockholders.

Our Charter provides that the authorized number of directors may be changed only by resolution of the Board. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one-third of the directors. The division of our Board into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control of our company. Subject to the special rights of the holders of one or more outstanding series of preferred stock to elect directors, our directors may be removed only for cause by the affirmative vote of the holders of at least 75% of our outstanding voting stock entitled to vote in the election of directors. The Board currently has one vacancy that we are currently looking to fill.

Board Committees

Our Board directs the management of our business and affairs, as provided by Delaware law, and conducts its business through meetings of the Board and standing committees. We have a standing audit committee, nominating and corporate governance committee and compensation committee. In addition, from time to time, special committees may be established under the direction of the Board when necessary to address specific issues.

Audit Committee

Our audit committee is responsible for, among other things:

appointing, compensating, retaining, evaluating, terminating and overseeing our independent registered public accounting firm;

discussing with our independent registered public accounting firm their independence from management;

reviewing, with our independent registered public accounting firm, the scope and results of their audit;

approving all audit and permissible non-audit services to be performed by our independent registered public accounting firm;

overseeing the financial reporting process and discussing with management and our independent registered public accounting firm the quarterly and annual financial statements that we file with the SEC;

overseeing our financial and accounting controls and compliance with legal and regulatory requirements;

reviewing our policies on risk assessment and risk management;

reviewing related person transactions; and

establishing procedures for the confidential anonymous submission of concerns regarding questionable accounting, internal controls or auditing matters.

Our audit committee consists of Messrs. Flynn, Mr. Gorovitz and Mr. Hurvitz, with Mr. Flynn serving as chair. Rule 10A-3 of the Exchange Act and the Nasdaq rules require that our audit committee be composed entirely of independent members. Our Board has affirmatively determined that Messrs. Flynn, Mr. Gorovitz, and Mr. Hurvitz each meet the definition of “independent director” for purposes of serving on the audit committee under Rule 10A-3 of the Exchange Act and the Nasdaq rules. Each member of our audit committee also meets the financial literacy requirements of Nasdaq listing standards. In addition, our Board has determined that Messrs. Flynn and Gorovitz each qualify as an “audit committee financial expert,” as such term is defined in Item 407(d)(5) of Regulation S-K. Our Board has adopted a written charter for the audit committee.

Compensation Committee

Our compensation committee is responsible for, among other things:

reviewing and approving the corporate goals and objectives, evaluating the performance of and reviewing and approving, (either alone or, if directed by our Board, in conjunction with a majority of the independent members of the Board) the compensation of our Chief Executive Officer;

overseeing an evaluation of the performance of and reviewing and setting or making recommendations to our Board regarding the compensation of our other executive officers;

reviewing and approving or making recommendations to our Board regarding our incentive compensation and equity-based plans, policies and programs;

reviewing and approving all employment agreement and severance arrangements for our executive officers;

making recommendations to our Board regarding the compensation of our directors; and

retaining and overseeing any compensation consultants.

Our compensation committee consists of Messrs. Flynn, Mr. Gorovitz, and Mr. Hurvitz with Mr. Flynn serving as chair. Mr. Hurvitz was appointed to the compensation committee on March 30, 2023 and Mr. Troy served on this committee until July 18, 2022 when his term on the board of directors terminated. Our Board has affirmatively determined that Messrs. Flynn and Gorovitz each meet the definition of “independent director” for purposes of serving on the compensation committee under the Nasdaq rules, including the heightened independence standards for members of a compensation committee, and are “non-employee directors” as defined in Rule 16b-3 of the Exchange Act. Our Board has adopted a written charter for the compensation committee.

Nominating and Corporate Governance Committee

Our nominating and corporate governance committee is responsible for, among other things:

identifying individuals qualified to become members of our Board, consistent with criteria approved by our Board;

overseeing succession planning for our Chief Executive Officer and other executive officers;

periodically reviewing our Board’s leadership structure and recommending any proposed changes to our Board;

overseeing an annual evaluation of the effectiveness of our Board and its committees; and

developing and recommending to our Board a set of corporate governance guidelines.

Our nominating and corporate governance committee consists of Dr. Glied, Mr. Hurvitz, and Dr. Javitt, with Dr. Glied serving as chair. Mr. Hurvitz was appointed to the compensation committee on March 30, 2023 and Mr. Troy served on this committee until July 18, 2022 when his term on the board of directors terminated. Our Board has affirmatively determined that Dr. Glied and Mr. Hurvitz each meet the definition of “independent director” under the Nasdaq rules. The Board has determined that the appointment of Dr. Javitt, the founder of the Company, to the Nominating and Corporate Governance Committee is required by the best interests of the Company and its shareholders. The Board believes Dr. Javitt’s unique experience, qualifications and contributions to the Company create an exceptional and limited set of circumstances that will be useful in the identification and nomination of potential new Board members. Dr. Javitt’s term on the Nominating and Corporate Governance Committee will expire on May 24, 2023.

Risk Oversight

Our Board is responsible for overseeing our risk management process. Our Board focuses on our general risk management strategy, the most significant risks facing us, and oversees the implementation of risk mitigation strategies by management. Our audit committee is also responsible for discussing our policies with respect to risk assessment and risk management. Our Board believes its administration of its risk oversight function has not negatively affected our Board’s leadership structure.

Compensation Committee Interlocks and Insider Participation

None of our executive officers serves as a member of the Board or compensation committee (or other committee performing equivalent functions) of any entity that has one or more executive officers serving on our Board or compensation committee.

Code of Business Conduct and Ethics

We adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A copy of the code is posted on our corporate website at www.nrxpharma.com. In addition, we intend to post on our website all disclosures that are required by law or the Nasdaq listing standards concerning any amendments to, or waivers from, any provision of the code. The information contained in, or accessible through, our website does not constitute a part of this Form 10-K/A. We have included our website address in this Form 10-K/A solely as an inactive textual reference.

Item 11. Executive Compensation

EXECUTIVE COMPENSATION

Our “Named Executive Officers” for the year ended December 31, 2022 include (i) Stephen Willard, our Chief Executive Officer, (ii) Jonathan Javitt, our Chief Scientist and former Chief Executive Officer, (iii) Robert Besthof, our former Chief Commercial Officer and former Interim Chief Executive Officer, (iv) Seth Van Voorhees, our Chief Financial Officer and Treasurer, (v) Rick Panicucci, our Chief Technology Officer, (vi) Ira Strassberg, our former Chief Financial Officer, and (vii) Alessandra Daigneault, former Chief Corporate Officer, General Counsel and Secretary.

2022 Summary Compensation Table

The following table presents information regarding the total compensation of our Named Executive Officers for the years ended December 31, 2022 and December 31, 2021.

Name and Principal Position	Year	Salary ($)		Bonus ($)⁽¹⁾		Stock Awards ($)⁽²⁾		Option Awards ($)⁽³⁾			All Other Compensation ($)⁽⁴⁾		Total ($)
Stephen Willard⁽⁵⁾ Chief Executive Officer	2022		233,871		—		566,000		—			—		799,871
Jonathan Javitt⁽⁶⁾ Chief Scientist and former Chief Executive Officer	2022		919,758		—		—		—		$	6,250		926,008
	2021		275,000		—		—		—			102,287		377,287
Robert Besthof⁽⁷⁾ Former Chief Commercial and former Interim Chief Executive Officer	2022		436,559		—		—		195,000			—		631,559
	2021		264,000		—		—		—			—		264,000
Seth Van Voorhees⁽⁸⁾ Chief Financial Officer and Treasurer	2022		220,000		—		—		134,875			—		354,875
Rick Panicucci Chief Technology Officer	2022		220,000		—		—		—			—		220,000
Ira Strassberg⁽⁹⁾ Former Chief Financial Officer and Treasurer	2022		216,375		—		—		1,000,875	⁽¹¹⁾		—		1,217,250
Alessandra Daigneault⁽¹⁰⁾ Former Chief Corporate Officer, General Counsel and Secretary	2022		162,844		290,000		—		—			132,000		584,844
	2021		228,000		290,000		—		1,754,611			2,961		2,275,572

(1)

Amount reported for Ms. Daigneault in 2022 reflects (i) $60,000 awarded as a discretionary bonus; (ii) $100,000 awarded as a transaction bonus; and (iii) $130,000 in reimbursement for Ms. Daigneault’s exercise of stock options.

(2)

Amount reflects the grant date fair value of restricted stock granted as an employment inducement award during fiscal year 2022 as calculated in accordance with ASC Topic 718, excluding the effect of estimated forfeitures. See Note 10 to the consolidated financial statements contained in the Form 10-K for information regarding the assumptions used in calculating this amount.

(3)

Amount reflects the grant date fair value of stock options granted during fiscal year 2022 or fiscal year 2021 as calculated in accordance with ASC Topic 718, excluding the effect of estimated forfeitures. See Note 10 to the consolidated financial statements contained in the Form 10-K for information regarding the assumptions used in calculating these amounts.

(4)

For 2022, the All Other Compensation column reflects: (i) for Mr. Javitt, $6,250 for his service as chairman of the Board during the first quarter of 2022; and (ii) for Ms. Daigneault, $132,000 in severance payments.

(5)

Mr. Willard was appointed Chief Executive Officer on July 12, 2022.

(6)

Mr. Javitt retired from his role as Chief Executive Officer on March 8, 2022. As of March 8, 2022, Mr. Javitt assumed the role of Chief Scientist and remained on the Company’s board of directors.

(7)

Mr. Besthof was appointed Interim Chief Executive Officer on March 8, 2022. Prior to such date, Mr. Besthof served as Chief Commercial Officer. Following Mr. Willard’s appointment as Chief Executive Officer on July 12, 2022, Mr. Besthof resumed his role as Chief Commercial Officer. Mr. Besthof’s employment terminated on April 30, 2023.

(8)

Dr. Van Voorhees was appointed Chief Financial Officer and Treasurer on June 6, 2022, effective June 13, 2022.

(9)

Mr. Strassberg’s employment terminated on July 7, 2022.

(10

Ms. Daigneault’s employment terminated on July 22, 2022.

(11)

Mr. Strassberg’s option grant was forfeited in its entirety in connection with his termination.

(8)

Dr. Van Voorhees was appointed Chief Financial Officer and Treasurer on June 6, 2022, effective June 13, 2022.

(9)

Mr. Strassberg’s employment terminated on July 7, 2022.

(10

Ms. Daigneault’s employment terminated on July 22, 2022.

(11)

Mr. Strassberg’s option grant was forfeited in its entirety in connection with his termination.

Narrative to Summary Compensation Table

Base Salaries and Compensation

NRx’s Named Executive Officers receive an annual base salary or annual rate of compensation to compensate them for services rendered to NRx. The base salary or annual rate of compensation payable to each Named Executive Officer is intended to provide a fixed component of compensation reflecting the executive’s skill set, experience, role and responsibilities. For 2022, (i) Mr. Willard’s annual base salary was set at $500,000; (ii) Dr. Javitt’s annual base salary was set at $275,000 until March 8, 2022; following March 8, 2022, Dr. Javitt’s annual consulting fee was set at $1,000,000; (iii) Mr. Besthof’s annual consulting fee was set at $264,000 until March 8, 2022; following March 8, 2022, Mr. Besthof’s annual consulting fee was approximately $500,000; (iv) Dr. Van Voorhees’s annual base salary was set at $400,000; (v) Mr. Panicucci’s annual base salary was set at $220,000; (vi) Mr. Strassberg’s annual base salary was set at $400,000; and (vii) Ms. Daigneault’s annual base salary was set at $264,000.

Cash Bonus Compensation

Pursuant to their employment agreements, Mr. Willard, Dr. Van Voorhees, and Mr. Strassberg are eligible to receive a discretionary annual performance-based cash bonus with a target equal to 50% of base salary. Pursuant to his employment agreement, Dr. Javitt was eligible to receive a discretionary annual performance-based cash bonus with a target equal to $275,000. Pursuant to her employment agreement, Ms. Daigneault was eligible to receive a discretionary annual performance-based cash bonus with a target equal to 20% of base salary plus an additional $100,000 for each successful financing transaction. Pursuant to his consulting agreement, Mr. Panicucci is eligible to receive a discretionary annual cash bonus of $50,000 upon achievement of certain performance objectives. Pursuant to Mr. Besthof’s letter agreement, he was eligible to receive a special payment for calendar year 2022 equal to $250,000 at target based on achievement of performance metrics determined by the Board.

Equity Compensation

We typically grant stock options pursuant to the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan (the “Omnibus Plan”) as the long-term incentive component of our compensation program. Stock options allow employees, including our Named Executive Officers, to purchase shares of our Common Stock at a price equal to the fair market value of our Common Stock on the date of grant. Our stock options have vesting schedules that are designed to encourage continued employment and typically vest in substantially equal installments on each of the first three anniversaries of the applicable vesting commencement date, subject to the recipient’s continued service through each applicable vesting date. From time to time, our Board may also construct alternate vesting schedules as it determines appropriate to motivate particular employees, as further described below.

Option Awards

Dr. Van Voorhees, Mr. Besthof, and Mr. Strassberg were granted options to purchase 325,000, 100,000 and 425,000 shares of Common Stock in 2022, respectively. Mr. Strassberg’s options were forfeited for no consideration in connection with his termination.

Mr. Besthof received a grant of 100,000 options in March 2022 (the “Besthof 2022 Options”) that vested on the one year anniversary of the grant date. The Besthof 2022 Options are described below under “Potential Payments upon Termination or Change in Control – Besthof Agreement”.

Refer to the “Outstanding Equity Awards at 2022 Fiscal Year End” table below for additional information regarding these options.

Willard Restricted Stock Award

As an inducement to join the Company, Mr. Willard received a grant of 1,000,000 shares of restricted stock. Such grant of restricted stock was designed to comply with the NASDAQ inducement exemption and was granted outside of the Company’s existing equity compensation plans. However, the restricted stock award is governed in all respects as if issued under the Omnibus Plan. The shares of restricted stock will vest in substantially equal installments on each of the first three anniversaries of the date of grant, subject to Mr. Willard’s continued employment with, appointment as a director of, or engagement to provide services to, the Company through the applicable vesting date.

Mr. Willard’s shares of restricted stock are subject to clawback if Mr. Willard engages in conduct that is in conflict with or adverse to the Company’s interests while employed by the Company, including violating non-competition, non-solicitation, and non-disparagement covenants.

Refer to the “Outstanding Equity Awards at 2022 Fiscal Year End” table below for additional information regarding these shares of restricted stock.

Executive Employment Arrangements

Willard Employment Agreement

In connection with his commencement of employment with us in July 2022, we entered into an employment agreement with Mr. Willard (the “Willard Employment Agreement”) pursuant to which he serves as our Chief Executive Officer and on our Board. The Willard Employment Agreement provides for an initial two-year term and extends automatically for additional one-year periods unless either party provides notice of termination. The Willard Employment Agreement provides for an annual base salary of $500,000, a performance-based bonus with a minimum target of 50% of base salary (with such bonus for 2022 pro-rated based on the number of days employed), and an inducement grant of 1,000,000 shares of restricted stock that vests over a three-year period.

The Willard Employment Agreement includes (i) a confidentiality covenant that applies during the term of employment and for three years following termination, (ii) assignment of intellectual property, (iii) a non-competition covenant that applies during the term of employment and for 12 months following termination, and (iv) non-solicitation of employees and customers covenants that apply during the term of employment and for 12 months following termination.

Javitt Employment Agreement and Javitt Consulting Agreement

In connection with his commencement of employment with us in May 2015, we entered into an employment agreement with Dr. Javitt (the “Javitt Employment Agreement”) pursuant to which he served as our Chief Executive Officer and President. The Javitt Employment Agreement provided for an initial five-year term and extended automatically for additional one-year periods unless either party provided notice of termination. The Javitt Employment Agreement provided for a base salary of $275,000, subject to periodic increase by the Board. The Javitt Employment Agreement was terminated on March 8, 2022 when Dr. Javitt retired and became a consultant to the Company. Upon entering into the Javitt Consulting Agreement (as defined below), Dr. Javitt waived his rights to the bonus, severance and certain other provisions under the Javitt Employment Agreement.

Pursuant to a consulting agreement between the Company and Dr. Javitt, dated as of March 8, 2022 (the “Javitt Consulting Agreement”), Dr. Javitt will provide consulting services to the Company for a one-year period, including reviewing and providing scientific and strategic advice to the Company’s executive officers. The Javitt Consulting Agreement provided for an annual consulting fee of $1,000,000, with $250,000 paid within 10 days of the Javitt Consulting Agreement’s effective date and the remaining $750,000 payable in monthly installments of $75,000, subject to continued service.

The Javitt Consulting Agreement provides that the confidentiality, non-competition and non-solicitation covenants from the Javitt Employment Agreement continue to apply during the term of Dr. Javitt’s service and during the three-year period (with respect to the confidentiality covenant) or 12-month period (with respect to the non-competition and non-solicitation covenants) thereafter.

The Company may terminate the Javitt Consulting Agreement without prior notice immediately upon a termination for Cause. Dr. Javitt may terminate the Javitt Consulting Agreement upon 30 days’ notice at any time and for any reason. Upon termination of Javitt Consulting Agreement, the Company will pay Dr. Javitt any consulting fees and expenses that have been accrued but not yet paid. “Cause” is defined in the Javitt Consulting Agreement as: (i) Dr. Javitt’s gross negligence or willful misconduct, or willful and continued failure to substantially perform his duties (other than due to physical or mental illness or incapacity), which, in either case, causes material injury to the reputation or business of the Company; (ii) Dr. Javitt’s conviction of, or plea of guilty or nolo contendere to, a felony or other crime; (iii) Dr. Javitt’s fraud or embezzlement or other material misuse of funds or property belonging to the Company; or (iv) any material breach by Dr. Javitt under the Javitt Consulting Agreement subject to a 10 day notice and cure period (if reasonably capable of cure).

The Javitt Consulting Agreement was amended on March 29, 2023 (the “Javitt Consulting Agreement Amendment”). The Javitt Consulting Agreement Amendment provides for an initial period ending on March 8, 2024, subject to successive one-year terms unless either party provides notice of termination. The Javitt Consulting Agreement Amendment provides for: (i) an annual consulting fee of $575,000, payable in monthly installments; (ii) eligibility for an annual performance-based bonus with a minimum target of $250,000 (with the annual bonus, if any, for 2023 pro-rated based on the number of days during the 2023 calendar year following March 8, 2023 that Dr. Javitt is engaged by the Company); and (iii) subject to Board approval, a grant of 500,000 shares of restricted stock that will vest (x) 50% on the date upon which the Food and Drug Administration files the Company’s new drug application for the Antidepressant Drug Regimen (as defined therein) and (y) 50% on the date upon which the Food and Drug Administration has both approved the Company’s Antidepressant Drug Regimen and listed the Company’s Antidepressant Drug Regiment in the Food and Drug Administration’s “Orange Book.”

Besthof Agreement

Mr. Besthof was engaged by NeuroRx as Chief Commercial and Patient Officer and Head of Operations pursuant to the terms of a “Work For Hire” Agreement between NeuroRx and REBes Consulting LLC - Robert Besthof, dated as of March 1, 2016, which was amended as of October 23, 2020 (as amended, the “Besthof Agreement”).

The Besthof Agreement provides for an initial one-year term and extends automatically for additional one-month periods unless NeuroRx provides written notice of non-renewal at least 10 days prior to the expiration of the term, or unless Mr. Besthof’s services are terminated. The Besthof Agreement provides for a consulting fee, which was equal to $22,000 per month in 2022.

The Besthof Agreement includes an (i) assignment of intellectual property covenant, (ii) confidentiality covenant that applies for the greater of (x) a two-year period after the date of disclosure or (y) a two-year period from the end of the term of the Besthof Agreement, and (iii) non-contract covenant pursuant to which Mr. Besthof will not contract with any third party to manufacture or assist in the manufacture of an NMDA-based treatment for bipolar depression that applies for the term of the Besthof Agreement and for two years following the termination of the Besthof Agreement.

Effective March 8, 2022, Mr. Besthof, on behalf of his personal services corporation, entered into a letter agreement with the Company (the “Besthof Letter Agreement”). The Besthof Letter Agreement supplements the Besthof Agreement. The Besthof Letter Agreement provides for an aggregate monthly payment of $41,667 (of which $19,667 was for services as the Interim Chief Executive Officer) to Mr. Besthof for total annual payments at an annual rate of approximately $500,000 and a special payment for 2022 of up to $250,000 based on achievement of certain performance metrics to be determined by the Board. The Besthof Letter Agreement also provided for the grant of the Besthof 2022 Options. Pursuant to the Besthof Letter Agreement, Mr. Besthof was entitled to the additional payment $19,667 per month as Interim Chief Executive Officer for at least six months, unless he resigned or was terminated for “cause” (as defined in the Besthof Letter Agreement). The Besthof Letter Agreement also provides Mr. Besthof with customary indemnification and directors and officers insurance coverage.

Van Voorhees Employment Agreement

In connection with his commencement of employment with us in June 2022, we entered into an employment agreement with Dr. Van Voorhees (the “Van Voorhees Employment Agreement”) pursuant to which he serves as our Chief Financial Officer and Treasurer. The Van Voorhees Employment Agreement provides for an initial two-year term and extends automatically for additional one-year periods unless either party provides notice of termination. The Van Voorhees Employment Agreement provides for an annual base salary of $400,000, a performance-based bonus with a target of 50% of base salary, and a grant of 325,000 stock options that vest over a two-year period, with 162,500 options vesting on June 5, 2023 and 162,500 options vesting on June 5, 2024.

The Van Voorhees Employment Agreement includes (i) a confidentiality covenant that applies during the term of employment and for three years following termination, (ii) assignment of intellectual property, (iii) a non-competition covenant that applies during the term of employment and for 12 months following termination, and (iv) non-solicitation of employees and customers covenants that apply during the term of employment and for 12 months following termination.

Panicucci Consulting Agreement

Mr. Panicucci and NeuroRx entered into a consulting agreement effective as of January 7, 2021 (the “Panicucci Consulting Agreement”). The Panicucci Consulting Agreement provides for: (i) a consulting fee of $20,000 per month for approximately 20 hours of service per week; (ii) a grant of 25,000 stock options that vest in substantially equal installments over a three-year period; and (iii) an annual bonus of $50,000 upon achievement of certain objectives. The Panicucci Consulting Agreement will continue in effect until terminated by either party.

The Panicucci Consulting Agreement includes a confidentiality covenant that applies for a period of two years after the date of disclosure or two years from the end of the consulting term, whichever is greater.

Strassberg Employment Agreement

In connection with his commencement of employment with us in March 2022, we entered into an employment agreement with Mr. Strassberg (the “Strassberg Employment Agreement”) pursuant to which he served as our Chief Financial Officer and Treasurer. The Strassberg Employment Agreement provided for an initial two-year term and extended automatically for additional one-year periods unless either party provided notice of termination. The Strassberg Employment Agreement provided for an annual base salary of $400,000, a performance-based bonus with a minimum target of 50% of base salary, and a grant of 425,000 stock options that vest over a two year period, with 212,500 options vesting on March 15, 2023 and 212,500 options vesting on March 15, 2024. In connection with his termination, Mr. Strassberg’s options were forfeited for no consideration.

The Strassberg Employment Agreement includes (i) a confidentiality covenant that applies during the term of employment and for three years following termination, (ii) assignment of intellectual property, (iii) a non-competition covenant that applies during the term of employment and for 12 months following termination, and (iv) non-solicitation of employees and customers covenants that apply during the term of employment and for 12 months following termination.

Daigneault Employment Agreement

Effective September 1, 2021, we entered into an employment agreement with Ms. Daigneault (the “Daigneault Employment Agreement”) pursuant to which she served as Chief Corporate Officer, General Counsel, Corporate Secretary and, prior to March 8, 2022, Acting Treasurer. The Daigneault Employment Agreement provided for an initial one-year term and extended automatically for additional one-year periods unless either party provides notice of termination or non-renewal. The Daigneault Employment Agreement provided for a base salary of $264,000, subject to periodic increase by the Board. Pursuant to the Daigneault Employment Agreement, Ms. Daigneault was also eligible to receive (a) a performance-based bonus with a minimum target of 20% of base salary and (b) an additional transactional bonus of $100,000 upon consummation of a secondary offering or financing after September 1, 2021. The Daigneault Employment Agreement also provided Ms. Daigneault with an initial grant of 30,000 options, which vested monthly over a two-year period. In connection with her termination, the unvested portion of equity awards held by Ms. Daigneault was forfeited for no consideration.

The Daigneault Employment Agreement includes (i) a confidentiality covenant that applies during the term of employment and for three years following termination, (ii) assignment of intellectual property, (iii) a non-competition covenant that applies during the term of employment and for 12 months following termination, and (iv) non-solicitation of employees and customers covenants that apply during the term of employment and for 12 months following termination.

Under the terms of the Daigneault Employment Agreement, Ms. Daigneault was entitled to participate in all employee benefit plans, programs and arrangements made available to other U.S.-based employees generally.

Outstanding Equity Awards at 2022 Fiscal Year End

The following table summarizes the number of shares of Common Stock underlying outstanding equity incentive plan awards for each Named Executive Officer as of December 31, 2022.

	Option Awards									Stock Awards
Name	Vesting Commencement Date		Number of Securities Underlying Unexercised Options (#) Exercisable		Number of Securities Underlying Unexercised Options (#) Unexercisable		Option Exercise Price ($)		Option Expiration Date	Number of shares or units of stock that have not vested (#)		Market value of shares or units of stock that have not vested ($)(1)		Equity incentive plan awards: number of unearned shares, units or other rights that have not vested (#)		Equity incentive plan awards: market or payout value of unearned shares, units or other rights that have not vested ($)
Stephen Willard	7/12/2022	(2)		—		—		—	—		1,000,000		1,110,000		—		—

Jonathan Javitt	—			—		—		—	—		—		—		—		—

Robert Besthof	3/1/2016			247,200		—		0.20	2/28/2026		—		—		—		—

	5/24/2021	(3)		138,880		208,320		3.08	10/23/2030		—		—		—		—

	3/8/2022	(4)		—		100,000	2.61		3/8/2032		—		—		—		—

	Option Awards									Stock Awards
Name	Vesting Commencement Date		Number of Securities Underlying Unexercised Options (#) Exercisable		Number of Securities Underlying Unexercised Options (#) Unexercisable		Option Exercise Price ($)		Option Expiration Date	Number of shares or units of stock that have not vested (#)		Market value of shares or units of stock that have not vested ($)(1)		Equity incentive plan awards: number of unearned shares, units or other rights that have not vested (#)		Equity incentive plan awards: market or payout value of unearned shares, units or other rights that have not vested ($)
Seth Van Voorhees	6/13/2022	(5)		—		325,000		0.51	6/12/2032		—		—		—		—

Rick Panicucci	—			—		—	—		—		—		—		—		—

Ira Strassberg	—			—		—	—		—		—		—		—		—

Alessandra Daigneault	—			—		—	—		—		—		—		—		—

(1)

Market value is based on the closing sale price of our common stock on December 31, 2022 of $1.11.

(2)

These shares of restricted stock vest in substantially equal installments on each of the first three anniversaries of the grant date, subject to continued service.

(3)

These stock options vest in substantially equal installments on October 23, 2023, October 23, 2024, and October 23, 2025.

	(4)	These stock options vested on March 8, 2023.

(5)

These stock options vest over a two-year period, with 162,500 options vesting on June 13, 2023 and 162,500 options vesting on June 13, 2024, subject to continued service.

Health, Welfare and Retirement Plans

We do not maintain a 401(k) defined contribution plan or any other employee benefit plans or programs.

Clawback

The Board is reviewing the final rule issued by the SEC implementing the provisions of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to recoupment of incentive-based compensation and will adopt a compliant clawback policy when the NASDAQ adopts listing standards in accordance with the final rules.

Potential Payments upon Termination or Change in Control

Willard Employment Agreement

In the event Mr. Willard’s employment is terminated due to his death or disability, by the Company for Cause, or by Mr. Willard without Good Reason, the Company will pay to Mr. Willard (or his beneficiary or estate, as applicable): (i) base salary earned but not paid through the date of termination, (ii) pay for any vacation time earned but not used through the date of termination, (iii) any annual bonus earned for the year preceding the year of termination but unpaid on the date of termination and (iv) any business expenses incurred but not reimbursed on the date of termination.

In the event Mr. Willard’s employment is terminated by the Company without Cause, upon a Change of Control (as defined in the Willard Employment Agreement) or upon Mr. Willard’s resignation for Good Reason, subject to Mr. Willard’s execution and non-revocation of a general release of claims, the Company will pay Mr. Willard: (i) continued base salary payments for the period beginning on the termination date and ending on the first anniversary of the termination date; and (ii) all accrued compensation and a prorated target bonus through the date of termination.

“Cause” is defined in the Willard Employment Agreement as: (i) Mr. Willard’s failure to perform (other than by reason of disability), or gross negligence in the performance of, his material duties and responsibilities to the Company (unauthorized absence for a period of five consecutive business days will be considered failure to perform); (ii) material breach of the confidentiality covenant or assignment of rights to intellectual property covenant or breach of any fiduciary duty owed to the Company; (iii) fraud or embezzlement or other dishonesty which is material (monetarily or otherwise) with respect to the Company; (iv) indictment, conviction or plea of nolo contendere to a felony or other crime involving moral turpitude that is material to the Company; (v) Mr. Willard’s material breach of the Willard Employment Agreement or of any Company policy; or (vi) disciplinary proceedings or other events that impair Mr. Willard’s ability to function as Chief Executive Officer of the Company.

“Good Reason” is defined in the Willard Employment Agreement as: (i) material diminution of Mr. Willard’s compensation or benefits; (ii) material diminution of Mr. Willard’s title, duties, authority or responsibilities; (iii) the Company’s material breach of any term of the Willard Employment Agreement; (iv) the failure of the Board to nominate Mr. Willard to fill one of the vacant seats on the Board; or (v) the required relocation of Mr. Willard’s place of employment to a location that is more than 25 miles from his home.

Javitt Consulting Agreement

Besthof Agreement

If, following a change in control, either (a) Mr. Besthof’s assigned and required place of work is more than 50 miles from his home or (b) there is a substantial and material diminution in his duties or title, Mr. Besthof will have the right to terminate for good reason and will be entitled to receive fee payment continuation at his current rate of $22,000 for a period of 12 months and (c) 12 months of health care coverage under an equivalent to the employer plan at “gold level” or a supplemental payment equivalent to the health insurance premium payment under any such plan.

If, following a change in control, Mr. Besthof is terminated without cause (which is not defined in the Besthof Agreement), Mr. Besthof is entitled to receive (i) fee payment continuation at his current rate of $22,000 for a period of 12 months and (ii) 12 months of health care coverage under an equivalent to the employer plan at “gold level” or a supplemental payment equivalent to the health insurance premium payment under any such plan.

Besthof Letter Agreement

Pursuant to the Besthof Letter Agreement, if Mr. Besthof was terminated by the Company without “cause” prior to the Company hiring a permanent chief executive officer or, under limited circumstances, he resigned, he may have received separation payments of up to six months of pay, the special payment, to the extent not yet paid, and vesting of the Besthof 2022 Options.

Van Voorhees Employment Agreement

In the event Mr. Van Voorhees’ employment is terminated due to his death or disability, by the Company for Cause, or by Mr. Van Voorhees without Good Reason, the Company will pay to Mr. Van Voorhees (or his beneficiary or estate, as applicable): (i) base salary earned but not paid through the date of termination, (ii) pay for any vacation time earned but not used through the date of termination, (iii) any annual bonus awarded for the year preceding the year of termination but unpaid on the date of termination and (iv) any business expenses incurred but not reimbursed on the date of termination.

In the event Mr. Van Voorhees’s employment is terminated by the Company without Cause, upon a Change of Control (as defined in the Van Voorhees Employment Agreement) or upon Mr. Van Voorhees’ resignation for Good Reason, subject to Mr. Van Voorhees’ execution and non-revocation of a general release of claims, the Company will pay Mr. Van Voorhees: (i) continued base salary payments for the period beginning on the termination date and ending on the nine month anniversary of the termination date; (ii) all accrued compensation and a prorated target bonus through the date of termination; and (iii) all unvested equity compensation held by Mr. Van Voorhees will vest and become fully exercisable.

“Cause” is defined in the Van Voorhees Employment Agreement as: (i) Mr. Van Voorhees’ failure to perform (other than by reason of disability), or gross negligence in the performance of, his material duties and responsibilities to the Company (unauthorized absence for a period of five consecutive business days will be considered failure to perform); (ii) material breach of the confidentiality covenant or assignment of rights to intellectual property covenant or breach of any fiduciary duty owed to the Company; (iii) fraud or embezzlement or other dishonesty which is material (monetarily or otherwise) with respect to the Company; (iv) indictment, conviction or plea of nolo contendere to a felony or other crime involving moral turpitude that is material to the Company; or (v) loss of CPA licensure, disciplinary proceedings or other events that impair Mr. Van Voorhees’ ability to function as Chief Financial Officer or Treasurer of the Company.

“Good Reason” is defined in the Van Voorhees Employment Agreement as: (i) material diminution of Mr. Van Voorhees’ compensation or benefits; (ii) material diminution of Mr. Van Voorhees’ title, duties, authority or responsibilities; (iii) the Company’s material breach of any term of the Van Voorhees Employment Agreement; or (iv) the relocation of Mr. Van Voorhees’ place of employment to a location that is more than 20 miles from his home.

Panicucci Consulting Agreement

Upon termination of the Panicucci Consulting Agreement, the Company will pay Mr. Panicucci (or his estate, if applicable) any earned but unpaid consulting fees and reimbursement of business expenses.

Strassberg Employment Agreement

In the event Mr. Strassberg’s employment is terminated due to his death or disability, by the Company for Cause, or by Mr. Strassberg without Good Reason, the Company will pay to Mr. Strassberg (or his beneficiary or estate, as applicable): (i) base salary earned but not paid through the date of termination, (ii) pay for any vacation time earned but not used through the date of termination, (iii) any annual bonus awarded for the year preceding the year of termination but unpaid on the date of termination and (iv) any business expenses incurred but not reimbursed on the date of termination.

In the event Mr. Strassberg’s employment is terminated by the Company without Cause, upon a Change of Control (as defined in the Strassberg Employment Agreement) or upon Mr. Strassberg’s resignation for Good Reason, subject to Mr. Strassberg’s execution and non-revocation of a general release of claims, the Company will pay Mr. Strassberg: (i) continued base salary payments for the period beginning on the termination date and ending on the one year anniversary of the termination date; (ii) all accrued compensation and a prorated target bonus through the date of termination; and (iii) all unvested equity compensation held by Mr. Strassberg will vest and become fully exercisable.

“Cause” is defined in the Strassberg Employment Agreement as: (i) Mr. Strassberg’s failure to perform (other than by reason of disability), or gross negligence in the performance of, his material duties and responsibilities to the Company (unauthorized absence for a period of five consecutive business days will be considered failure to perform); (ii) material breach of the confidentiality covenant or assignment of rights to intellectual property covenant or breach of any fiduciary duty owed to the Company; (iii) fraud or embezzlement or other dishonesty which is material (monetarily or otherwise) with respect to the Company; (iv) indictment, conviction or plea of nolo contendere to a felony or other crime involving moral turpitude that is material to the Company; or (v) loss of CPA licensure, disciplinary proceedings or other events that impair Mr. Strassberg’s ability to function as Chief Financial Officer or Treasurer of the Company.

“Good Reason” is defined in the Strassberg Employment Agreement as: (i) material diminution of Mr. Strassberg compensation or benefits; (ii) material diminution of Mr. Strassberg’s title, duties, authority or responsibilities; (iii) the Company’s material breach of any term of the Strassberg Employment Agreement; or (iv) the relocation of Mr. Strassberg’s place of employment to a location that is more than 20 miles from his home.

Daigneault Employment Agreement

In the event Ms. Daigneault was terminated by us without Cause or upon a Change of Control, subject to her execution of a release of claims, in addition to the Final Compensation (as defined below), she would have been entitled to receive (i) severance pay equal to the base salary then in effect through the six month anniversary of the termination date (the “Daigneault Severance Pay”), (ii) accrued compensation not yet paid and (iii) a prorated bonus through the date of termination. In connection with Ms. Daigneault’s termination with the Company on July 22, 2022, she received severance pay equal to six months of her base salary.

“Cause” is defined in the Daigneault Employment Agreement as Ms. Daigneault’s (i) failure to perform (other than by reason of disability), or serious negligence in the performance of, her material duties and responsibilities to the Company (unauthorized absence of Ms. Daigneault for a period of five business days will be considered failure to perform); (ii) material breach of confidentiality or intellectual property provisions contained in the employment agreement or breach of any fiduciary duty owed to the Company; (iii) fraud or embezzlement or other dishonesty which is material (monetarily or otherwise) with respect to the Company; (iv) indictment, conviction or plea of nolo contendere to a felony or other crime involving moral turpitude that is material to the Company; or (v) loss of legal licensure, legal disciplinary proceedings, or other events that impair Ms. Daigneault’s ability to function as Corporate Secretary of the Company.

Pursuant to the terms of the Daigneault Employment Agreement, in the event Ms. Daigneault was terminated due to death or disability, the executive or her beneficiaries, as applicable, would have been entitled to (i) base salary earned but not paid through the date of termination, (ii) pay for any vacation time earned but not used through the date of termination, (iii) any annual bonus awarded for the year preceding that in which termination occurs but unpaid on the date of termination and (iv) any business expenses incurred but not reimbursed on the date of termination (all of the foregoing, the “Final Compensation”).

Equity Incentive Awards

Pursuant to the Omnibus Plan, in the event of a Change in Control (as defined in the Omnibus Plan): (i) if the acquirer or successor company in such Change in Control has agreed to provide for the substitution, assumption, exchange or other continuation of the stock options, then, if the Named Executive Officer’s employment with or service to the Company is terminated by the Company without Cause (as defined in the Omnibus Plan) (and other than due to death or disability) on or within 24 months following a Change in Control, then all of the Named Executive Officer’s options will become immediately exercisable; (ii) if the acquirer or successor company in such Change in Control has not agreed to provide for the substitution, assumption, exchange or other continuation of the options, all options held by the Named Executive Officer will become immediately exercisable; and (iii) the Committee (as defined in the Omnibus Plan) may cancel any outstanding options in exchange for cash, securities or other property equal to the value of such canceled options.

Willard Restricted Stock Award

If Mr. Willard’s employment with the Company is terminated without Cause (other than for death or disability) or Mr. Willard resigns for Good Reason (each as defined in Mr. Willard’s employment agreement, and such termination, a “Qualifying Termination”), Mr. Willard will vest in a pro rata portion of the restricted stock. In the event of a Qualifying Termination on or within 12 months following a Change in Control (as defined in the Omnibus Plan), all of the shares of restricted stock will vest. If Mr. Willard’s service terminates for any other reason, all unvested shares of restricted stock will be forfeited for no consideration.

COMPENSATION OF DIRECTORS

Pursuant to our Director Compensation Program, each member serving on our Board during 2022 was eligible to compensation for his or her service, as follows.

Board of Directors member: $60,000 annual retainer plus an annual equity grant

Chairman of the Board: $25,000 annual retainer

Board Committee Chair: $15,000 annual retainer

Board Committee Member: $10,000 annual retainer

2022 Director Compensation

The following table shows for the fiscal year ended December 31, 2022 certain information with respect to the compensation of our non-employee directors. As Named Executive Officers, Mr. Willard’s and Dr. Javitt’s compensation is shown in the 2022 Summary Compensation Table. Mr. Willard did not receive any additional compensation for his service on the Board.

Name	Fees Earned or Paid in Cash ($)		Option Awards ($)(1)		Total ($)
Patrick Flynn	$	90,000	$	90,000	$	180,000
Sherry Glied	$	70,000	$	90,000	$	160,000
Aaron Gorovitz	$	80,000	$	90,000	$	170,000
Chaim Hurwitz	$	70,000	$	90,000	$	160,000
Dan Troy	$	85,000	$	—	$	85,000

(1)

Amounts reflect the full grant date fair value of stock options awarded under our Omnibus Plan during 2022, computed in accordance with the requirements of FASB ASC 718. The stock options vest on May 25, 2023. As of December 31, 2022, (i) Mr. Flynn held 166,505 outstanding options, (ii) Dr. Glied held 231,942 outstanding options, (iii) Mr. Gorovitz held 166,505 outstanding options, and (iv) Mr. Hurwitz held 166,505 outstanding options.

EQUITY COMPENSATION PLAN INFORMATION

The following table provides certain aggregate information with respect to our equity compensation plans in effect as of December 31, 2022.

Plan Type	Number of securities to be issued upon exercise of outstanding options, warrants and rights			Weighted-average exercise price of outstanding options, warrants and rights		Number of shares of common stock remaining available for future issuance under equity compensation plans
Equity compensation plans approved by security holders⁽¹⁾		3,452,615	(2)(3)	$	1.12		299,784

Equity compensation plans not approved by security holders⁽⁴⁾		1,000,000			—		0

(1)

Includes awards granted pursuant to the Omnibus Plan.

(2)

As of December 31, 2022, there were 299,784 shares of common stock authorized for issuance pursuant to awards under the Omnibus Plan. Pursuant to the terms of the Omnibus Plan, the number of shares available for issuance thereunder will automatically increase each fiscal year beginning with fiscal year 2022 and ending with fiscal year 2031 by the lesser of (a) 1% of the total number of shares outstanding on the last day of the immediately preceding fiscal year on a fully diluted basis assuming that all shares available for issuance under the Omnibus Plan are issued and outstanding or (b) such number of shares determined by the Board.

(3)

Excludes rights outstanding under the 2016 Omnibus Incentive Plan. As of December 31, 2022, there were 1,487,521 securities to be issued upon exercise of outstanding options, warrants and rights pursuant to our 2016 Omnibus Incentive Plan, with a weighted-average exercise price of $3.72, which were assumed by Big Rock Partners Acquisition Group and converted into an option to acquire an adjusted number of shares of common stock at an adjusted exercise price per share in connection with the May 2021 merger. No further grants or awards will be made under the 2016 Omnibus Incentive Plan.

(4)

Reflects the grant of an “employment inducement grant” under NASDAQ Listing Rule 5635(c)(4) comprised of restricted stock granted to Mr. Willard.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

PRINCIPAL STOCKHOLDERS

The following table sets forth information with respect to the beneficial ownership of our Common Stock, as of April 27, 2023 by:

each person who is the beneficial owner of more than 5% of the outstanding shares of our Common Stock;

each of our named executive officers and directors; and

all of our executive officers and directors as a group.

Beneficial ownership for the purposes of the following table is determined in accordance with the rules and regulations of the SEC. A person is a “beneficial owner” of a security if that person has or shares “voting power”, which includes the power to vote or to direct the voting of the security, or “investment power”, which includes the power to dispose of or to direct the disposition of the security or has the right to acquire such powers within 60 days. Accordingly, we have included all shares of Common Stock issuable to such person upon the exercise of warrants or options currently exercisable or exercisable within 60 days of the date hereof. We did not deem such shares outstanding, however, for the purpose of computing the percentage ownership of any other person.

Unless otherwise noted in the footnotes to the following table, and subject to applicable community property laws, the persons and entities named in the table have sole voting and investment power with respect to their beneficially owned common stock and preferred stock.

Except as indicated in the footnotes to the table, each of the stockholders listed below has sole voting and investment power with respect to the shares of Common Stock owned by such stockholders. Unless otherwise noted, the address of each beneficial owner is c/o NRX Pharmaceuticals, Inc., 1201 Orange Street, Suite 600, Wilmington, DE 19801, Attention: Corporate Secretary.

The beneficial ownership of our Common Stock is based on 71,557,580 shares of Common Stock issued and outstanding as of April 27, 2023.

Beneficial Ownership Table

Name and Address of Beneficial Owners	Amount and Nature of Beneficial Ownership		Percent of Class
Officers and Directors
Stephen H. Willard (1)		1,050,000		1.47	%
Robert Besthof(2)		409,790		*
Riccardo Panicucci(3)		82,666		*
Seth Van Voorhees(4)		208,837		*
Patrick J. Flynn(5)		1,639,397		2.29	%
Sharon A. Glied, Ph.D.(6)		245,110		*
Aaron Gorovitz(7)		208,191		*
Chaim Hurvitz(8)		2,311,298		3.23	%
Jonathan Javitt(9)		14,468,329		20.22	%

All Executive Officers and Directors as a Group (9 persons)		20,623,618		28.82	%
All Greater than 5% Holders
Glytech, LLC(10)		9,634,793		13.46	%

Indicates less than 1%

(1)

Consists of (i) 50,000 shares of Common Stock held by Stephen H. Willard individually and (ii) 1,000,000 shares of restricted Common Stock that can be voted but cannot be traded. 333,333 shares will be unrestricted on July 12, 2023, an additional 333,333 shares on July 12, 2024 and the remaining 333,334 shares on July 12, 2025. Mr. Willard’s address is 1201 Orange Street, Suite 600 Wilmington, DE 19801.

(2)

Consists of (i) 23,710 shares of Common Stock held by Robert Besthof individually and (ii) 245,963 shares of common stock subject to options held by Robert Besthof which are vested and exercisable within 60 days; does not include 307,520 shares subject to unvested options held by Robert Besthof which are not exercisable within 60 days. Mr. Besthof’s address is 1201 Orange Street, Suite 600 Wilmington, DE 19801.

(3)

Consists of 82,666 shares of Common Stock options held by Riccardo Panicucci that have vested; does not include 41,334 unvested options held by Mr. Panicucci that are not exercisable within 60 days. Mr. Panicucci’s address is 1201 Orange Street, Suite 600 Wilmington, DE 19801.

(4)

Consists of (i) 46,337 shares of Common Stock held by Seth Van Voorhees individually and (ii) 162,500 shares that are vesting and exercisable within 60 days; does not include 162,500 unvested options held by Mr. Voorhees that are not going to vest and be exercisable within 60 days. Mr. Voorhees’ address is 1201 Orange Street, Suite 600 Wilmington, DE 19801.

(5)

Consists of (i) 362,332 shares of Common Stock held by Nash-Flynn Investments, LLC, (ii) 226,254 shares of common stock held by the Whitney Pritchard Nash Flynn 2010 Trust and the Lindsay Pritchard Nash Flynn 2010 Trust, (iii) 882,556 shares of common stock issuable upon exercise of fully vested warrants held by the Whitney Pritchard Nash Flynn 2010 Trust and the Lindsay Pritchard Nash Flynn 2010 Trust, (iv) 1,750 shares of common stock held by Patrick Flynn and (v) 166,505 shares of Common Stock options, of which 3,845 shares are vested and exercisable and 162,660 shares are going to vest and be exercisable within 60 days. Patrick Flynn is the owner of Nash-Flynn Investments, LLC and trustee of the Whitney Pritchard Nash Flynn 2010 Trust and the Lindsay Pritchard Nash Flynn 2010 Trust. Mr. Flynn’s address is 1201 Orange Street, Suite 600 Wilmington, DE 1980.

(6)

Consists of (i) 13,168 shares of Common Stock held by Cottingham-Hillcrest, Inc. and (ii) 231,942 shares of Common Stock subject to options held by Sharon A. Glied, Ph.D. of which 69,282 are vested and exercisable and 162,660 are going to vest and be exercisable within 60 days. Dr. Glied’s address is 1201 Orange Street, Suite 600 Wilmington, DE 1980.

(7)

Consists of (i) 8,336 shares of Common Stock held by Samuel David Gorovitz 2017 Irrevocable Trust, (ii) 8,336 shares of Common Stock held by Jeremy Paul Gorovitz 2017 Irrevocable Trust, (iii) 8,336 shares of Common Stock held by Marisa Shey Gorovitz 2017 Irrevocable Trust, (iv) 16,678 shares of Common Stock held by Elizabeth Gorovitz (the holder’s spouse), and (v) 166,505 shares of Common Stock options, of which 3,845 are vested and exercisable and 162,660 are going to vest and be exercisable within 60 days. Aaron Gorovitz is the trustee of the Samuel David Gorovitz 2017 Irrevocable Trust, the Jeremy Paul Gorovitz 2017 Irrevocable Trust, and the Marisa Shey Gorovitz 2017 Irrevocable Trust. Elizabeth Gorovitz is the wife of Aaron Gorovitz; does not include 20,843 shares issuable upon achievement of earnouts. Mr. Gorovitz’s address is 1201 Orange Street, Suite 600 Wilmington, DE 1980.

(8)

Consists of (i) 1,436,350 shares of Common Stock held by Shirat HaChaim Ltd., (ii) 208,443 shares of Common Stock held by CH Health-Private Venture Capital Ltd, (iii) 500,000 shares of Common Stock held by Chaim Hurvitz individually, and (iv) 166,505 shares of Common Stock options, of which 3,845 have vested and exercisable and 162,660 which are going to vest and be exercisable within 60 days. Chaim Hurwitz is the owner of Shirat HaChaim Ltd. and CH Health-Private Venture Capital Ltd. Mr. Hurvitz's address is 1201 Orange Street, Suite 600 Wilmington, DE 1980.

(9)

Consists of (i) 12,599,997 shares of common stock held by the Jonathan Javitt Living Trust, (ii) 1,422,000 shares of common stock held by The Javitt 2012 Irrevocable Dynasty Trust, (iii) 146,332 shares of common stock held by Jonathan Javitt individually and (iv) 300,000 held by the Jonathan Javitt Donor Advised Fund. Jonathan Javitt is the trustee of the Jonathan Javitt Living Trust, the Grantor of The Javitt 2012 Irrevocable Dynasty Trust and the donor and primary advisor of the Jonathan Javitt Donor Advised Fund. Dr. Javitt’s address is 1201 Orange Street, Suite 600 Wilmington, DE 1980.

(10)

Consists of 9,643,234 shares of Common Stock held by Glytech, LLC. Glytech, LLC is owned by Daniel Javitt, who is the brother of Jonathan Javitt, a director and Chief Scientist of the Company. Glytech LLC’s address is 1201 N. Market Street, Suite 111, Wilmington, DE 19801.

Item 13. Certain Relationships and Related Transactions, and Director Independence

CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

The following includes a summary of transactions since January 1, 2022 to which we have been a party in which the amount involved exceeded or will exceed $120,000, and in which any of our directors, executive officers or, to our knowledge, beneficial owners of more than 5% of our capital stock or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than transactions that are described under the “Executive and Director Compensation” section of this Form 10-K/A. We also describe below certain other transactions with our directors, executive officers and stockholders.

Private Placement Lock-Up Agreement

On February 2, 2022, we consummated a private placement (the “Private Placement”) pursuant to the terms and conditions of that certain Securities Purchase Agreement, dated as of January 30, 2022 (the “Purchase Agreement”), with certain investors. In connection with the closing of the Private Placement, we entered into a lock-up agreement with Jonathan Javitt and Daniel Javitt (collectively, the “Javitt Stockholders”), dated as of January 30, 2022 (the “Private Placement Lock-Up Agreement”), pursuant to which the Javitt Stockholders agreed not to transfer, directly or indirectly, any Common Stock owned by them for sixty (60) days following the Effective Date (as defined in the Purchase Agreement) (the “Restriction Period”). Subject to certain conditions, the Javitt Stockholders may transfer shares of Common Stock provided that: (i) we receive a signed lock-up letter agreement for the balance of the Restriction Period from each transferee, prior to such transfer, (ii) the transfer does not involve a disposition for value, (iii) the transfer is not required to be reported with the SEC in accordance with the Exchange Act, as amended, and no report of such transfer is made voluntarily, and (iv) neither the Javitt Stockholders nor any transferee, as the case may be, otherwise voluntarily effects any public filing or report regarding such transfer, with respect to certain specified transfers under the Private Placement Lock-Up Agreement. The Restriction Period has now expired.

Procedures with Respect to Review and Approval of Related Person Transactions

Our Board recognizes the fact that transactions with related persons present a heightened risk of conflicts of interests (or the perception of such conflicts of interest). We have adopted a written policy on transactions with related persons that is in conformity with the requirements for issuers having publicly held common stock that is listed on the Nasdaq. Under the policy, our legal department is primarily responsible for developing and implementing processes and procedures to obtain information regarding related persons with respect to potential related person transactions and then determining, based on the facts and circumstances, whether such potential related person transactions do, in fact, constitute related person transactions requiring compliance with the policy. If the legal department determines that a transaction or relationship is a related person transaction requiring compliance with the policy, our general counsel will be required to present to the audit committee all relevant facts and circumstances relating to the related person transaction. The audit committee will be required to review the relevant facts and circumstances of each related person transaction, including if the transaction is on terms comparable to those that could be obtained in arm’s length dealings with an unrelated third party and the extent of the related person’s interest in the transaction, take into account the conflicts of interest and corporate opportunity provisions of the our code of business conduct and ethics, and either approve or disapprove the related person transaction. If advance audit committee approval of a related person transaction requiring the audit committee’s approval is not feasible, then the transaction may be preliminarily entered into by management upon prior approval of the transaction by the chair of the audit committee, subject to ratification of the transaction by the audit committee at the audit committee’s next regularly scheduled meeting; provided, that if ratification is not forthcoming, management will make all reasonable efforts to cancel or annul the transaction. If a transaction was not initially recognized as a related person transaction, then, upon such recognition, the transaction will be presented to the audit committee for ratification at the audit committee’s next regularly scheduled meeting; provided, that if ratification is not forthcoming, management will make all reasonable efforts to cancel or annul the transaction. Our management will update the audit committee as to any material changes to any approved or ratified related person transaction and will provide a status report at least annually of all then-current related person transactions. No director will be permitted to participate in approval of a related person transaction for which he or she is a related person.

Support Services

We license patents owned by Glytech LLC, which is solely owned by Daniel C. Javitt, the brother of Jonathan Javitt, a director and Chief Scientist of the Company. During 2022 and 2021, the Company in 2022 and NeuroRx, Inc., the predecessor to our company, in 2021 paid Glytech LLC $250,000 and $250,000, respectively, for continuing research and development, technology support services and reimbursed expenses. These support services are ongoing. Glytech LLC’s support includes both non-clinical and clinical research in support of the expansion of our intellectual property portfolio.

In addition, we pay Zachary Javitt, the son Jonathan Javitt, on an hourly basis for services related to website, IT, and marketing support under the supervision of our Chief Executive Officer, who is responsible for assuring that the services are provided on financial terms that are at market. We paid Zachary Javitt a total of $133,445 and $106,500 during the years ended December 31, 2022 and 2021, respectively.

The Company also seeks services for digital health product development from PillTracker to monitor the use of Aviptadil, a drug, in clinical trials. Zachary Javitt is PillTracker’s Chief Executive Officer and Jonathan Javitt is the chairman of its board of directors. The Company paid approximately $170,340.00 and $820,293.88 to PillTracker for its services in 2022 and 2021, respectively.

Controlled Company Status

From the consummation of the business combination that formed the Company in March 2021 and through October 2021, the Company qualified as a “controlled company” pursuant to the listing rules of The Nasdaq Stock Market (“Nasdaq”). In accordance with such rules, a company that has ceased to be a “controlled company” within the meaning of the Nasdaq listing rules shall be permitted to phase-in the requirement to have a majority independent board and independent nominations and compensation committees on the same schedule as companies listing with their initial public offering. Accordingly, the Company was required to be fully compliant with the requirement to have a majority independent board, compensation committee and nominations committee by October 2022.

Director Independence

Our Board has determined that Sharon A. Glied, Patrick J. Flynn, Aaron Gorovitz, and Chaim Hurvitz are “independent directors” as defined in the Nasdaq listing standards and applicable SEC rules.

Item 14. Principal Accountant Fees and Services

KPMG LLP has served as our independent auditor since 2018. The Company incurred the following fees from KPMG LLP for the audit of the consolidated financial statements and for other services provided during the years ended December 31, 2022 and 2021.

	For the year ended December 31
	2022		2021
Audit fees (1)	$	775,000	$	798,600
Audit-related fees (2)	$	0	$	0
Tax fees (3)	$	0	$	0
All other fees (4)	$	0	$	0
Total fees	$	775,000	$	798,600

(1)

Audit fees consist of fees for professional services rendered in connection with the audit of our annual consolidated financial statements, the review of the interim consolidated financial statements included in quarterly reports, services rendered in connection with the May 2021 merger and follow-on public offering, and additional public offerings.

(2)

There were no audit-related fees billed in 2022 or 2021.

(3)

There were no tax-related fees billed in 2022 or 2021.

(4)

There were no other fees billed in 2022 or 2021.

Audit Committee Pre-Approval Policy and Procedures

Consistent with requirements of the SEC and the Public Company Accounting Oversight Board regarding auditor independence, our audit committee is responsible for the appointment, compensation, and oversight of the work of our independent registered public accounting firm. In recognition of this responsibility, our audit committee (or the chair if such approval is needed on a time urgent basis) pre-approves audit and permissible non-audit services provided by the independent registered public accounting firm. These services include audit services, audit-related services, tax services and other services.

Part IV.

Item 15. Exhibits, Financial Statement Schedules

(a) List of Documents filed.

The financial statements of NRx Pharmaceuticals, Inc. are filed as part of the original Form 10-K.

The schedules have been omitted from the Form 10-K because they are not required or because the information is provided elsewhere in the financial statements. The financial statements of unconsolidated subsidiaries are omitted because, considered in the aggregate, they would not constitute a significant subsidiary.

(b) List of Exhibits.

The following is a list of exhibits filed with this Form 10-K/A.

		Incorporated by Reference Exhibit
Exhibit Number	Description	Form	Exhibit	Filing Date	File Herewith
10.54	Settlement Agreement by and between Relief Therapeutics Holding AG, Relief Therapeutics International SA, NeuroRx, Inc. and NRX Pharmaceuticals, Inc., dated November 12, 2022.				X
10.55	Asset Purchase Agreement by and between Relief Therapeutics Holding AG, Relief Therapeutics International SA, NeuroRx, Inc. and NRX Pharmaceuticals, Inc., dated November 12, 2022.				X
31.1	Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.				X
31.2	Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.				X
101	Interactive data files pursuant to Rule 405 of Regulation S-T formatted in Inline XBRL: (i) Consolidated Balance Sheets as of December 31, 2021 and December 31, 2020; (ii) Consolidated Statements of Operations for the years ended December 31, 2021 and 2020; (iii) Consolidated Statements of Changes in Stockholders’ Equity (Deficit) for the years ended December 31, 2021 and 2020; (iv) Consolidated Statements of Cash Flows for the years ended December 31, 2021 and 2020; and (v) Notes to Financial Statements
104	Cover Page Interactive Data File (formatted in iXBRL and contained in Exhibit 101)

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on May 1, 2023.

	NRX PHARMACEUTICALS, INC.

	By:	/s/ Seth Van Voorhees
		Seth Van Voorhees
		Chief Financial Officer (Principal Financial Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report on Form 10-K has been signed by the following persons in the capacity and on the dates indicated.

Name	Position	Date
/s/ Stephen H. Willard	Chief Executive Officer and Director	May 1, 2023
Stephen H. Willard	(Principal Executive Officer)

/s/ Seth Van Voorhees	Chief Financial Officer	May 1, 2023
Seth Van Voorhees	(Principal Financial and Accounting Officer)

/s/ Patrick J. Flynn
Patrick J. Flynn	Director	May 1, 2023

/s/ Sharon A. Glied
Sharon A. Glied	Director	May 1, 2023

/s/ Aaron Gorovitz
Aaron Gorovitz	Director	May 1, 2023

/s/ Chaim Hurvitz
Chaim Hurvitz	Director	May 1, 2023

/s/ Jonathan C. Javitt
Jonathan C. Javitt	Director	May 1, 2023

EX-10.54 2 tm2314196d1_ex10-54.htm EXHIBIT 10.54

Exhibit 10.54

SETTLEMENT AGREEMENT

This Settlement Agreement (including Exhibit A) (this “Settlement Agreement”) is made and entered into as of this 12^th day of November, 2022 (the “Execution Date”), by and between Relief Therapeutics Holding AG and Relief Therapeutics International SA (together, "Relief"), on the one hand, and NEURORX, INC. ("NeuroRx") and NRX PHARMACEUTICALS, INC. ("NRx," and together with NeuroRx, the "NeuroRx Parties"), on the other hand. For all purposes, Relief and the NeuroRx Parties are each individually a "Party" and all are collectively the “Parties”).

RECITALS

A.            WHEREAS, Relief and NeuroRx entered into a Binding Collaboration Agreement, dated as September 18, 2020 (the "Collaboration Agreement"), which established the terms under which the Parties would collaborate and assist each other with the development and future sale of aviptadil, including but not limited to intravenous and inhalation use primarily as a treatment for COVID-19;

B.            WHEREAS, on October 6, 2021, Relief filed a complaint against NeuroRx and Jonathan Javitt ("Javitt"), NeuroRx's former Chief Executive Officer, in the Supreme Court of the State of New York, County of New York (the "Court"), captioned Relief Therapeutics Holding AG and Relief Therapeutics International SA (f/k/a Therametrics Discovery AG) v. Jonathan Cogswell Javitt and NeuroRx, Inc. (Index No. 655857/2021), alleging claims for (1) breach of the Collaboration Agreement, (2) breach of covenant of good faith and fair dealing, (3) declaratory judgment, (4) an accounting, and (5) tortious interference with prospective economic advantage (the "Relief Action");

C.            WHEREAS, on January 10, 2022, NeuroRx filed a complaint in the Supreme Court of the State of New York, County of New York, captioned, NeuroRx, Inc. v. Relief Therapeutics Holding AG and Relief Therapeutics International SA (f/k/a Therametrics Discovery AG) (Index No. 650162/2022), alleging claims for (1) breach of the Collaboration Agreement, (2) declaratory judgment, and (3) defamation (the "NeuroRx Action" and together with the Relief Action, the "Litigations");

D.            WHEREAS, on July 6, 2022, Judge Jennifer Schecter of the New York Supreme Court entered an order consolidating the Relief Action and the NeuroRx Action under Index No. 655857/2021;

E.            WHEREAS, without conceding the merit or lack of merit of any claim or defense or the existence of any liability whatsoever, the Parties now wish to fully and finally settle and resolve all disputes and differences that exist or heretofore have ever existed between them, respectively, including the claims asserted in the Relief Action, the NeuroRx Action, and all related claims, demands, rights of action, and causes of action, whether known or unknown;

F.            WHEREAS, on the Execution Date, [Redacted].

G.            WHEREAS, contemporaneously with the execution of this Settlement Agreement, the NeuroRx Parties and Relief are executing an Asset Purchase Agreement (the “Asset Purchase Agreement”), to which this Settlement Agreement is an exhibit, pursuant to which the NeuroRx Parties will sell to Relief, and Relief will purchase from the NeuroRx Parties, certain assets, as more particularly set forth in the Asset Purchase Agreement;

H.            WHEREAS, the settlement terms set forth in this Settlement Agreement shall become effective upon the Closing; and

I.             WHEREAS, subject to the Closing, the Parties desire to settle the Litigations on the terms set forth in this Settlement Agreement.

NOW THEREFORE, in consideration of the foregoing Recitals, and the mutual promises, covenants, and undertakings contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

Definitions

1.1

“Affiliate” means, with respect to any specified Person, any other Person that, directly or indirectly, through one or more intermediaries, controls, is controlled by or is under common control with such specified Person. The term "control" (including, with correlative meaning, the terms "controlled by" and "under common control with"), as used with respect to any Person, means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through the ownership of equity, voting securities, beneficial interest, by contract or otherwise.

1.2

“Business Day” means any day that is not a Saturday, a Sunday or other day on which banks are required or authorized by law to be closed in the State of New York.

1.3

“Closing” means the closing under the Asset Purchase Agreement pursuant to which the NeuroRx Parties and Relief will consummate the purchase and sale of the Transferred Assets (as defined in the Asset Purchase Agreement) and the other transactions contemplated by the Asset Purchase Agreement.

1.4

“Closing Date” means the date of the closing date under the Asset Purchase Agreement.

1.5

"Compound" means avipdadil.

1.6

“FDA” means the U.S. Food and Drug Administration (and any successor organization or agency thereto).

1.7

"Litigations" means the Relief Action and the NeuroRx Action.

1.8

"Product" means any product containing the Compound as an active ingredient for all routes of administration. Relief has historically called the Product RLF-100^® (and it is referred to as such in the Collaboration Agreement) and NRx has historically called the Product Zyesami^®.

1.9

"Transferred Assets" means the assets being transferred by the NeuroRx Parties to Relief under the Asset Purchase Agreement, as more particularly set forth in the Asset Purchase Agreement.

1.10

"SEC" means the United States Securities and Exchange Commission.

1.11

“Settlement Documents” means this Settlement Agreement, including the Stipulation of Dismissal (Exhibit A). [Redacted].

1.12

“Third Party” means any person or entity other than a Party or its Affiliates.

Stipulations.

2.1

On the Closing Date, as provided in the Asset Purchase Agreement, the NeuroRx Parties will transfer, deliver and convey the Transferred Assets to Relief.

2.2

On the Closing Date, in consideration of the mutual benefits of entering into this Settlement Agreement and the Asset Purchase Agreement:

(a)

the Parties shall enter into and cause to be filed with the Court in the Litigations, within three (3) Business Days after the Closing Date, the Stipulation of Dismissal in the form annexed hereto as Exhibit A dismissing the Litigations with prejudice, with each Party bearing its own costs and expenses and attorney's fees. If the Court does not dismiss the Litigations with prejudice substantially in the form annexed hereto as Exhibit A, the Parties agree to confer in good faith as to an alternative resolution; and

(b)

The Collaboration Agreement shall be terminated and shall be of no further force or effect.

Mutual General Releases. Effective on the Closing Date, except as set forth below, the Parties hereby mutually release, acquit, satisfy and forever discharge each and every other Party and all of their respective Affiliates, successors, assigns, employees, directors, officers, agents, attorneys, and other representatives of and from any and all charges, claims, counterclaims, actions, rights, demands, debts, liens, obligations, causes of action, liability, losses, damages, costs, expenses or accountings of any nature whatsoever, whether in law or in equity, whether known or unknown, suspected or unsuspected, from the beginning of time up to the date of the Settlement Agreement, arising under any circumstances whatsoever, including without limitation claims in any way related to: (i) the claims and counterclaims asserted in, and the conduct of, the Litigations; (ii) any counterclaims required to have been brought in the Litigations, and (iii) the conduct of the settlement negotiations; provided, however, that for the avoidance of doubt, excluding any claims arising from or under this Settlement Agreement or the Asset Purchase Agreement.

[Redacted].

The Parties have each made an investigation of the facts pertaining to this Settlement Agreement and to the released claims as each Party deems necessary. Each Party is aware that it may hereafter discover facts in addition to, contrary to, or different from those it now knows or believes to be true with respect to the matters set forth herein. Nevertheless, it is the intention of each Party to fully, finally, and forever settle and release all claims of any kind or nature whatsoever that were in existence as of the date of this Settlement Agreement. In furtherance of the Parties' intent, the release in this Agreement shall remain in full and complete effect notwithstanding the discovery or existence of any additional, contrary, or different facts.

Furthermore, each Party certifies that it has read the provisions of California Civil Code Section 1542 and has consulted its own counsel regarding that section. Each Party waives any and all rights under California Civil Code Section 1542 (or any other similar law in any jurisdiction), which states:

A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.

Each Party agrees and acknowledges that the released claims extend to and include unknown and unsuspected claims.

Legal Fees. Each Party will pay its own costs and expenses, including attorney fees, incurred in connection with the Litigations and in connection with the preparation, negotiation, and execution of this Settlement Agreement and its Exhibit.

Legal Compliance.

5.1

This Agreement, other than this Section 5 and Sections 8 through 21, shall not become effective until the Closing Date. Following the signing of this Agreement and the Asset Purchase Agreement, the Parties shall jointly ask the Court to stay the matter for a period of no more than an additional [thirty (30)] days to allow for the Closing of the transactions contemplated by the Asset Purchase Agreement. The Parties also agree to submit to the court appropriate stipulations and proposed orders for extensions of time for all due dates in the Litigations so that neither Party is required to incur unnecessary expenses in the Litigations between the Effective Date and the Closing Date.

5.2

In the event that the Closing under the Asset Purchase Agreement does not occur (as applicable) by the Closing Date (or such date as the Parties agree to in writing) and either Party, at its option pursuant to the Asset Purchase Agreement, elects to terminate the Asset Purchase Agreement, then (i) this Agreement (other than this Section 5 and Section 8) will automatically terminate, and (ii) the Parties will notify the Court that a settlement was not achieved and that the litigation schedule should resume on a schedule to be proposed by each Party and entered by the Court.

Final Agreement. This Settlement Agreement and its Exhibit, if not terminated pursuant to Section 5.2, constitutes a final settlement between the Parties and, following the Closing Date but without limiting Relief's obligations and the NeuroRx Parties’ rights under the Asset Purchase Agreement, the NeuroRx Parties shall not contest, challenge, dispute or deny in any way Relief's unilateral right to control the development of any aviptadil product (including the Product) containing the Compound anywhere in the world.

Publicity. After the Closing Date, (i) the Parties shall issue a joint press release announcing that the settlement of the Litigations has closed (the “Settlement”), and (ii) each of the Parties shall file the necessary disclosure with the SEC with respect to the Settlement, subject to Section 8 below and the Asset Purchase Agreement. The Parties shall jointly agree upon the contents, and timing for the issuance, of the joint press release. The obligations of Relief and NeuroRx to share information about their disclosure of the Settlement is more particularly set forth in the Asset Purchase Agreement.

Confidentiality. From and after the Execution Date and except as expressly provided in Section 7 (Publicity), the terms of this Settlement Agreement and its Exhibits will be maintained in strict confidence by the Parties except that any Party may disclose this Settlement Agreement (i) with the prior written consent of the other Party; (ii) to any governmental body having jurisdiction and specifically requiring such disclosure; (iii) in response to a valid subpoena or as otherwise may be required by law, legal process or order of a court; (iv) for the purposes of disclosure in connection with any reports filed with the SEC, including, without limitation, SEC reporting requirements, or by the rules or regulations of any stock exchange that the Parties are subject to; (v) as required during the course of litigation and subject to protective order; (vi) with obligations of confidentiality at least as stringent as those contained herein, to a counterparty in connection with a proposed merger, acquisition, asset sale, spin-out, debt or equity financing, or other corporate or business combination transaction; (vii) in connection with tax audits or to fulfill its corporate financial reporting obligations under GAAP or IFRS, as the case may be; (viii) with obligations of confidentiality at least as stringent as those contained herein, by any Party and its Affiliates as required to enforce this Agreement or establish rights or defenses hereunder; (ix) to officers, key shareholders, directors and/or employees with a need to know, who are under obligations of confidentiality at least as stringent as those contained herein; and (x) to its Affiliates, who are similarly bound by this Agreement or under obligations of confidentiality at least as stringent as those contained herein. The Parties may also disclose this Settlement Agreement and its Exhibit(s) to their respective attorneys, accountants, auditors, or similar individuals providing professional services to such Party in their capacity of advising the party in such matters, subject to obligations of confidentiality and/or privilege at least as stringent as those contained herein. The Parties acknowledge and agree that, upon the filing of the Stipulation of Dismissal with the Court, the fact that the Parties have settled the Litigations will be a matter of public record and will not be subject to any confidentiality restrictions, but the terms of such settlement will be maintained in confidence to the extent provided by this Section 8 and the confidentially provisions contained in the Asset Purchase Agreement. Prior to making any such disclosure pursuant to subparts 8(ii), (iii) or (v) above, the Party seeking disclosure shall promptly notify the other Party in sufficient time (if reasonably feasible) to permit the other Party the opportunity to object (or, if the timing of the litigation makes advance notice impracticable, the notice is provided within 10 days after the disclosure), to seek a court-entered protective order or comparable court-ordered restriction, and shall reasonably cooperate with the other Party in its efforts to obtain that protective order and take all other reasonable actions in an effort to minimize the nature and extent of such disclosure and obtain confidential treatment to the extent available. Notwithstanding anything else in this Agreement to the contrary, a Party may also disclose to anyone information that is publicly available.

Non-Disparagement. From the Execution Date of this Settlement Agreement, neither Relief and its Affiliates (including their officers and directors), nor the NeuroRx Parties and their Affiliates (including their officers and directors) shall in any way libel, defame or otherwise disparage any other Party, or its products or services, or that other Party's officers and directors. For purposes of this section, "disparage" shall mean the making or publication of any materially negative statement, whether written or oral, that has as its purpose or effect to lower someone's opinion of, or confidence in, the person concerning whom the false statement is made or of that person's knowledge, experience, reliability or competence. Notwithstanding the foregoing, testimony provided by any person subject to this Section 9 in response to a valid subpoena, or as otherwise required by law, legal process or order of a court, shall not violate this Section 9 so long as the information provided is truthful.

10.

No Assignment. This Settlement Agreement may not be assigned or transferred to a Third Party without the express prior written consent of the other Party hereto, except as set forth in the Asset Purchase Agreement. Any attempted assignment in violation of this Section 10 shall be void. Subject to the foregoing, this Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the Parties and their respective permitted successors and assigns.

11.

Entire Agreement. This Settlement Agreement and its Exhibit(s), together with the Asset Purchase Agreement, constitute the entire agreement between the Parties with respect to the subject matter hereof and supersede and terminate any prior or contemporaneous agreements and/or understandings between the Parties, whether oral or in writing, relating to such subject matter. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties other than as are set forth in this Settlement Agreement and in the Asset Purchase Agreement. No subsequent alteration, amendment, change, waiver, or addition to this Settlement Agreement will be binding upon the Parties unless reduced to a writing that both identifies itself as an amendment to this Settlement Agreement and is signed by an authorized officer of each Party. Each Party in deciding to execute this Settlement Agreement has been advised by counsel and has not relied on any understanding, agreement, representation or promise by the other Party that is not explicitly set forth herein or in the Asset Purchase Agreement.

12.

Governing Law. This Settlement Agreement shall be governed by and construed in accordance with the laws of the State of New York, without regard to conflict or choice of law principles. If any civil action is filed to enforce or interpret any of the terms or provisions of this Settlement Agreement, or otherwise, the Parties agree that the appropriate venue shall in the courts of New York, located in the County of New York, Borough of Manhattan. Each party hereby irrevocably submits to the exclusive jurisdiction of the courts of New York.

13.

Severability. If any provision of this Settlement Agreement is declared illegal, invalid or unenforceable by a court having competent jurisdiction, it is mutually agreed that this Settlement Agreement will endure except for the part declared invalid or unenforceable by order of such court; provided, however, that in the event that the terms and conditions of this Settlement Agreement are materially altered, the Parties will, in good faith, renegotiate the terms and conditions of this Settlement Agreement to reasonably replace such invalid or unenforceable provisions in light of the intent of this Settlement Agreement.

14.

Waiver. Any delay or failure in enforcing a Party’s rights under this Settlement Agreement, or any acquiescence as to a particular default or other matter, will not constitute a waiver of such Party’s rights to the enforcement of such rights, nor operate to bar the exercise or enforcement thereof at any time or times thereafter, except as to an express written and signed waiver as to a particular matter for a particular period of time.

15.

Counterparts. This Settlement Agreement may be executed simultaneously in several counterparts (including e-mail counterparts), each of which will be deemed an original as against a Party whose signature appears thereon, but all of which together will constitute one and the same instrument.

16.

Representations and Warranties. The Parties hereby represent and warrant that: (i) they have approved the execution of this Settlement Agreement by all necessary corporate action and have authorized and directed the signatory officers below to execute and deliver this Agreement; (ii) they each have the full corporate right and power to enter into this Settlement Agreement, and there are no other persons or entities whose consent or joinder in this Settlement Agreement is necessary to make fully effective those provisions of this Agreement that obligate, burden or bind them; (iii) when so executed by each Party, this Settlement Agreement will constitute a valid and binding obligation of such Party, enforceable in accordance with its terms, except as may be limited by bankruptcy and insolvency laws and subject to principles of equity; and (iv) they have not transferred or assigned or pledged to any Third Party or Affiliate the right to bring, pursue, or settle any of claims made in the Litigations.

17.

Execution Knowing and Voluntary. Each Party acknowledges and represents that it: (i) has fully and carefully read and considered this Settlement Agreement prior to its execution; (ii) has been or has had the opportunity to be fully apprised by an attorney of the legal effect and meaning of this document and all terms and conditions hereof; (iii) has had the opportunity to make whatever investigation or inquiry deemed necessary or appropriate in connection with the subject matter of this Settlement Agreement; (d) has been afforded the opportunity to negotiate as to any and all terms hereof; (v) is executing this Settlement Agreement voluntarily, free from any undue influence, coercion, duress, or fraud; (vi) no other Person or Party, nor any agent or attorney of a Party, made any promise, representation or warranty whatsoever, express or implied, not contained in this Agreement concerning the subject matter of this Settlement Agreement to induce it to execute this Settlement Agreement; (vii) it has not executed this Settlement Agreement in reliance on any promise, representation or warranty whatsoever, express or implied, not contained in this Agreement concerning the subject matter of this Settlement Agreement; and (viii) it has not executed this Settlement Agreement in reliance on any promise, representation or warranty not contained herein. The Parties included this paragraph to preclude any claim that any Party was fraudulently induced to execute this Settlement Agreement.

18.

Construction. This Settlement Agreement has been jointly negotiated and drafted by the Parties through their respective counsel and no provision will be construed or interpreted for or against any of the Parties on the basis that such provision, or any other provision, or the Agreement as a whole, was purportedly drafted by the particular Party. All references to periods of days for taking certain actions in this Settlement Agreement will be construed to refer to calendar days unless Business Days is specified. Capitalized terms used but not defined in this Settlement Agreement will have the meanings ascribed to them in the Asset Purchase Agreement.

19.

Captions. The captions of this Settlement Agreement are solely for convenience of reference and will not affect its interpretation.

20.

Negation of Agency. Nothing contained herein will be deemed to create any relationship, whether in the nature of agency, joint venture, partnership or otherwise, between Relief, on the one hand, and the NeuroRx Parties, on the other hand. No Party will be authorized to bind or obligate another Party in any manner.

21.

Covenant Not to Sue. Except as otherwise provided in this Settlement Agreement, in no circumstances shall Relief or any successor or assign of Relief seek any money or any other remedy of any kind from the NeuroRx Parties arising from a claim or counterclaim asserted in the Litigations, either as an alleged alter ego of Javitt or otherwise, and whether by way of judgment enforcement or otherwise and Relief covenants and agrees, except as otherwise provided in this Settlement Agreement, never to make any claim or allegation against the NeuroRx Parties arising out of any alleged alter ego status vis-à-vis Javitt as it relates to a claim or counterclaim asserted in the Litigations.

22.

Notice. Any notice required or permitted to be given or sent under this Settlement Agreement will be hand delivered or sent by express delivery service or certified or registered mail, postage prepaid, to the Parties at the addresses indicated below.

If to Relief:

RELIEF THERAPEUTICS Holding SA

Avenue de Sécheron 15

1202 Genève

Switzerland

Attention: Jack Weinstein, Chief Financial Officer

jack.weinstein@relieftherapeutics.com

with copies (which will not constitute notice hereunder) to:

Craig Weiner, Esq.

Akerman LLP

1251 Avenue of the Americas

New York, NY 10020

cweiner@akerman.com

and

Philip B. Schwartz, Esq.

Akerman LLP

201 East Las Olas Boulevard

Suite 1800

Fort Lauderdale, FL 33301

954-468-2455

pschwartz@akerman.com

If to the NeuroRx Parties:

NRx Pharmaceuticals, Inc.

1201 North Market Street

Suite 111

Wilmington, DE 19801

Attention: Stephen H. Willard, Chief Executive Officer

willard@nrxpharma.com

with copies (which will not constitute notice hereunder) to:

Douglas Boggs, Esq.

DLA Piper (US) LLP

500 8th Street, NW

Washington, DC 20004

202-799-4070

douglas.boggs@us.dlapiper.com

Any such notice will be deemed to have been received on the date actually received. Either Party may change its address by giving the other Party written notice, delivered in accordance with this Section 22.

[Signatures on Next Page]

IN WITNESS WHEREOF, this Settlement Agreement has been executed by the undersigned authorized representatives of the Parties as of the date and year first above written.

Relief Therapeutics Holding AG		NEURORX, INC.


By:	/s/ Stephen Willard	By:	/s/ Stephen Willard

Name:	Stephen Willard	Name:	Stephen Willard

Title:	Chief Executive Officer	Title:	Chief Executive Officer

Relief Therapeutics International SA		NRX PHARMACEUTICALS, INC.


By:	/s/ Paolo Galfetti	By:	/s/ Jeremy Meinen

Name:	Paolo Galfetti	Name:	Jeremy Meinen

Title:	Director	Title:	VP Finance, CAO

EXHIBIT A

Supreme court of the state of new york

countY of new york

Relief Therapeutics Holding AG, and Relief Therapeutics International SA (f/k/a Therametrics Discovery AG),

Plaintiffs,

-against-

Jonathan C. Javitt and NeuroRx, Inc.

Defendants.

Index No. 655857/2021

Hon. Jennifer G. Schecter

NeuroRx, Inc.,

Plaintiff,

-against-

Relief Therapeutics Holding AG, and Relief Therapeutics International SA (f/k/a Therametrics Discovery AG),

Defendants.

Index No. 650162/2022

Hon. Jennifer G. Schecter

STIPULATION OF DISMISSAL

IT IS HEREBY STIPULATED AND AGREED, by and between Relief Therapeutics Holding AG, and Relief Therapeutics International SA (f/k/a Therametrics Discovery AG) on the one hand, and NeuroRx, Inc. on the other hand, through their undersigned counsel of record, that these matters in the above actions are hereby dismissed, WITH PREJUDICE.

Notwithstanding the foregoing, this Stipulation of Dismissal shall not release Jonathan Javitt from any claims brought by Relief Therapeutics Holding AG or Relief Therapeutics International SA (f/k/a Therametrics Discovery AG), and the above Actions shall continue as to Javitt.

Each party will bear its own attorneys’ fees and costs.

[SIGNATURE BLOCKS]

SO ORDERED:

This ________ day of ______________, 2022


	JENNIFER G. SCHECTER, J.S.C.

EX-10.55 3 tm2314196d1_ex10-55.htm EXHIBIT 10.55

Exhibit 10.55

ASSET PURCHASE AGREEMENT

This Asset Purchase Agreement (this "Agreement") is made and entered into as of November 12, 2022 (the "Execution Date"), by and between NRx Pharmaceuticals, Inc., a Delaware corporation ("NRx Pharma"), and its wholly-owned subsidiary, NeuroRx, Inc., a Delaware corporation ("NeuroRx", and collectively with NRx Pharma, "NRx"), on the one hand, and RELIEF THERAPEUTICS Holding SA, a corporation organized under the laws of Switzerland ("Holding"), and its wholly-owned subsidiary, Relief Therapeutics International SA, f/k/a Therametrics Discovery AG ("International", and collectively with Holding, "Relief"), on the other hand. NRx and Relief are sometimes referred to herein individually as a "Party" and collectively as the "Parties."

Recitals

A.             Holding, International, and NeuroRx are parties to that certain Binding Collaboration Agreement, dated as of September 18, 2020 (the "Collaboration Agreement"), which established the terms under which the Parties would collaborate and assist each other with the development and future sale of aviptadil, including but not limited to intravenous and inhalation use primarily as a treatment for COVID-19.

B.             The Parties have each filed suit in the Supreme Court of the State of New York for the county of New York, captioned (i) Relief Therapeutics Holding AG and Relief Therapeutics International SA (f/k/a Therametrics Discovery AG) v. Jonathan Cogswell Javitt ("Javitt") and NeuroRx, Inc. (Index No. 655857/2021), and (ii) NeuroRx, Inc. v. Relief Therapeutics Holding AG and Relief Therapeutics International SA (f/k/a Therametrics Discovery AG) (Index No. 650162/2022) (collectively, the "Litigations").

C.             In order to settle these disputes, simultaneously with the execution of this Agreement, the Parties (and the other parties to the Litigations other than Javitt) are executing a Settlement Agreement in the form attached hereto as Exhibit D ("Settlement Agreement"), which will, as of the Closing Date (as hereinafter defined), settle the Litigations between the Parties, and the Parties are entering into this Agreement pursuant to which NRx will sell to Relief, and Relief will purchase from NRx, the Transferred Assets (as defined below), all upon the terms and subject to the conditions set forth herein and in the Ancillary Agreements (the "Transactions").

D.             Under the Settlement Agreement, at the Closing Date the Collaboration Agreement shall be cancelled and shall be of no further force or effect.

In consideration of the mutual benefits to be derived from this Agreement and of the representations, warranties, conditions, agreements and promises contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows:

Agreement

SECTION 1. Definitions

1.1           "Affiliate" means, with respect to any specified Person, any other Person that, directly or indirectly, through one or more intermediaries, controls, is controlled by or is under common control with such specified Person. The term "control" (including, with correlative meaning, the terms "controlled by" and "under common control with"), as used with respect to any Person, means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through the ownership of equity, voting securities, beneficial interest, by contract or otherwise.

1.2           "Ancillary Agreements" means, collectively, the Patent Assignment Agreement in the form attached hereto as Exhibit A, the Assignment and Assumption Agreement in the form attached hereto as Exhibit B and the Bill of Sale in the form attached hereto as Exhibit C.

1.3           "Assumed Liabilities" has the meaning set forth in Section 2.3.

1.4           "Bankruptcy, Equity and Indemnity Exception" has the meaning set forth in Section 3.5.

1.5           "Business Day" means any day that is not a Saturday, a Sunday or other day on which banks are required or authorized by Law to be closed in the State of New York or the Canton of Geneva, City of Geneva, Switzerland.

1.6           "Calendar Half Year" means each successive period of six (6) calendar months commencing on January 1, and July 1, except that the first Calendar Half Year shall commence on the Closing Date and end on the day immediately prior to the first to occur of January 1 or July 1 after the Closing Date.

1.7           "Calendar Year" means each successive period of twelve (12) calendar months commencing on January 1 and ending on December 31, except that the first Calendar Year shall commence on the Closing Date and end on December 31, 2022.

1.8           "Claim Notice" has the meaning set forth in Section 7.3(b).

1.9           "Closing" has the meaning set forth in Section 2.5.

1.10         "Closing Date" has the meaning set forth in Section 2.5.

1.11         "Commercially Reasonable Efforts" means with respect to the efforts to be expended by a Party, with respect to any objective under this Agreement, reasonable, diligent, and good faith efforts to accomplish such objective as a reasonable party with the expertise that the relevant Party would normally use to accomplish a similar objective under similar circumstances, taking into account all reasonable factors and exercising reasonable business or legal judgment, as appropriate.

1.12         "Competing Product" means any product containing the Compound as an active ingredient, including the Product.

1.13         "Compound" means aviptadil, as further described on Schedule 1.13.

1.14         "Confidential Information" means all non-public information of a confidential or proprietary nature disclosed under this Agreement by or on behalf of a Party to the other Party (whether or not specifically labeled or identified as "confidential"), in any form or medium, including any such information that relates to the Transferred Assets, the Compound and the Product, and any rights or obligations under this Agreement. Confidential Information includes the following: (i) internal business information (including information relating to plans for studies, trials and formulations, strategic and staffing plans and practices, business, training, marketing, promotional and sales plans and practices, cost, rate and pricing structures, accounting and business methods and potential acquisition candidates); (ii) information that identifies individual requirements of, and specific contractual arrangements with, suppliers, distributors, customers, independent contractors or other business relations and their confidential information; (iii) Trade Secrets and other Know-How; and (iv) compilations of data and analyses, techniques, systems, formulae, research, records, reports, manuals, documentation, models, data and databases relating thereto; and inventions, innovations, improvements, developments, methods, designs, analyses, drawings, and reports. On and after the Closing Date, subject to Section 8.2, all Confidential Information relating solely to the Transferred Assets and the Product shall be deemed to be the Confidential Information of Relief, and NRx shall be deemed the receiving Party and Relief shall be deemed the disclosing Party with respect thereto.

1.15         "Controlling Party" has the meaning set forth in Section 7.3(c).

1.16         "COVID-19" means any disease, condition or ailment caused by, or associated with, or reasonably related to, the novel 2019 coronavirus, SARS-COV-2.

1.17         "Damages" means actual losses, costs, damages and expenses, including reasonable out-of-pocket attorneys’ fees and expenses, and reasonable fees and expenses of other professionals and experts (including any such reasonable costs, expenses and attorneys’ fees incurred in enforcing an Indemnified Party’s right to indemnification against any indemnifying Party, provided, however, that “Damages” shall not include punitive, incidental, consequential, special or indirect damages (including loss of revenue, diminution in value and any damages based on any type of multiple).

1.18         "Disclosure Schedule" means the disclosure schedule that has been prepared by NRx and delivered to Relief on the Execution Date.

1.19         "Dollars" or "$" means the legal tender of the United States.

1.20         "Execution Date" has the meaning set forth in the Preamble of this Agreement.

1.21         "Excluded Assets" has the meaning set forth in Section 2.2.

1.22         "Excluded Liabilities" has the meaning set forth in Section 2.4.

1.23         "FDA" means the United States Food and Drug Administration, or any successor agency thereto.

1.24         "FDCA" means the Federal Food, Drug and Cosmetic Act, as amended, and all related rules, regulations and guidelines.

1.25         "Field" means the treatment, prevention, detection, diagnosis, prognosis, palliation, monitoring or predisposition testing of any indication, disease or condition in humans.

1.26         "Governmental Authority" means any national, federal, regional, state, provincial, local or other governmental authority or instrumentality, legislative body, court, registrar (such as the United States Patent and Trademark Office), administrative agency, regulatory body or commission, including any multinational authority having governmental powers.

1.27         "IFRS" means International Financial Reporting Standards as issued by the International Accounting Standards Board, consistently applied.

1.28         "IND" means an application filed with a Regulatory Authority for authorization to commence clinical studies of a Product, including (i) an Investigational New Drug Application as defined in the FDCA, (ii) any equivalent of a United States IND in other countries or regulatory jurisdictions, and (iii) all supplements, amendments, variations, extensions, and renewals thereof.

1.29         "Indemnified Party" means the Person entitled to indemnification under Section 7 of this Agreement.

1.30         "Indemnifying Party" means the Party obligated to indemnify the Indemnified Party under Section 7.

1.31         "Intentionally Left Blank

1.32         "Knowledge" means, with respect to a particular fact or matter and a Party, the actual knowledge of any Knowledge Party of such Party, in each case following reasonable inquiry with respect to such fact or matter; provided, however, that such reasonable inquiry shall not require the Party to obtain a "freedom to operate" opinion or similar opinion of counsel or any Patent, trademark, or other intellectual property clearance search or review.

1.33         "Knowledge Party" means with respect to any Party, such Party's (i) Chief Executive Officer, (ii) Chief Scientific or Medical Officer, and (iii) Chief Legal Officer, or any individual employed by the Party who performs such tasks. For clarity, the NRx's Knowledge Parties include the individuals listed on Schedule 1.33.

1.34         "Know-How" means non-public proprietary knowledge, scientific information, formulae, processes, plans, technical information, new product information, test procedures, experience, data, technology, design information, Trade Secrets, and other information and knowledge, regardless of whether patentable or patented or not. The fact that a part of a compilation of data is in the public domain shall not prevent the compilation of data as such, or any one or more of the other elements of the compilation, from being Know-How.

1.35         "Know-How Confidential Information" has the meaning set forth in Section 3.6(h).

1.36         "Law" means any federal, state, local, municipal, foreign or other law, statute, constitution, common law, rule, regulation, executive order, injunction, judgment, order, award, decree, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Authority.

1.37         "Legal Proceeding" means any action, suit, charge, complaint, litigation, arbitration, proceeding (including any civil, criminal, administrative, investigative or appellate proceeding), hearing, inquiry, audit, examination or investigation commenced, brought, conducted or heard by or before, or otherwise involving, any court or other Governmental Authority or any arbitrator or arbitration panel. Legal Proceeding excludes office actions occurring in the course of prosecution of a trademark or a Patent.

1.38         "Liability" or "Liabilities" means any and all debts, liabilities, costs, assessments, expenses, claims, losses, and Damages.

1.39         "Lien" or "Liens" means any security interest, pledge, license, encumbrance, hypothecation, mortgage, deed of trust, conditional sales charge or other similar arrangement, or interest in real or personal property or other property, including intellectual property.

1.40         "Marketing Approval" means, with respect to a country or jurisdiction, any and all approvals (including approvals of NDAs), licenses, registrations, or authorizations of any Regulatory Authority or other Governmental Authority necessary for the commercial marketing and sale of the Product in such country or other jurisdiction.

1.41         "Material Adverse Effect" means an event, development, change, effect or circumstance that has had or could reasonably be expected to have a material and adverse effect on the Transferred Assets or the Assumed Liabilities taken as a whole; provided that the following shall not be deemed to constitute, and shall not be taken into account in determining whether there has been, a Material Adverse Effect: any adverse effect resulting from (a) general business or economic conditions affecting all industries (unless such conditions affect the Transferred Assets or Assumed Liabilities to a greater degree than other similar businesses), (b) conditions generally affecting the healthcare or pharmaceutical industry (unless such conditions affect the Transferred Assets or Assumed Liabilities to a greater degree than other similar businesses), (c) the announcement, execution or delivery of this Agreement or the pendency of the Transactions, or the taking of any action required by and in accordance with this Agreement, including the impact of any of the foregoing on the relationships, contractual or otherwise with any customers, suppliers, distributors, partners, employees or contractors or other business relations, (d) any change in IFRS or any change in applicable Laws or the interpretation thereof, (e) any change in geopolitical conditions, the outbreak or escalation of hostilities, any acts of war, sabotage, cyberattack or terrorism, or any escalation or worsening of any such acts of war, sabotage, cyberattack or terrorism threatened or underway as of the Execution Date of this Agreement, (f) the taking of any action by NRx at the request or with the consent of Relief, or (g) any epidemic, plague, pandemic or other outbreak of illness or public health event, hurricane, earthquake, flood or other natural disasters, acts of God or change resulting from weather conditions.

1.42         "NDA" means a New Drug Application, as defined in the FDCA.

1.43         "Net Sales" means:

[Redacted].

1.44         "Non-Competition Term" has the meaning set forth in Section 5.6.

1.45         "Non-Controlling Party" has the meaning set forth in Section 7.3(c).

1.46         "NRx Representative" has the meaning set forth in Section 3.6(f).

1.47         "NRX's Right to Try Program" means the program started by NRx relating to the use of the Product according to S.204, the "Trickett Wendler, Frank Mongiello, Jordan McLinn and Matthew Bellina Right to Try Act," and any national applications in force in the U.S. to the Execution Date.

1.48         "Patents" means all rights in United States and foreign patents and patent applications (including provisional applications) published or unpublished, filed or not yet filed and patent disclosures, and including, without limitation, all divisionals, utility patents, continuations, substitutions, continuations-in-part, re-examinations, re-issues, additions, renewals, extensions, confirmations, registrations, any confirmation patent or registration patent or patent of addition based on any such patent, patent term extensions, and supplemental protection certificates, and foreign counterparts of any of the foregoing.

1.49         "Permitted Liens" means any Lien: (i) caused by applicable Law that does not or would not be reasonably expected to detract from the current value of, or interfere with, the current use and enjoyment of any Transferred Asset subject thereto or affected thereby in the ordinary course of business of the development, manufacture or commercialization of the Product; (ii) arising under original purchase price conditional sales contracts and equipment leases with third parties entered into in the ordinary course of business that are transferred to Relief as part of the Transactions; and (iii) and other imperfections of title or Liens, if any, that have not had, and would not have, a Material Adverse Effect.

1.50         "Person" means any individual, Governmental Authority, corporation (including any nonprofit corporation), general partnership, limited partnership, limited liability partnership, joint venture, estate, trust, company (including any limited liability company or joint stock company), firm or other enterprise, association, organization, or entity.

1.51         "Pre-Closing Period" has the meaning set forth in Section 5.1.

1.52         "Product" means any product containing the Compound as an active ingredient for all routes of administration. Relief has historically called the Product RLF-100^® (and it is referred to as such in the Collaboration Agreement) and NRx has historically called the Product Zyesami^®.

1.53         "Regulatory Authority" means, in a particular country or regulatory jurisdiction, any applicable supranational, national, regional, state, or local regulatory agency, department, bureau, commission, council, or other Governmental Authority involved in regulating pharmaceutical products in such country or regulatory jurisdiction, including the FDA.

1.54         "Regulatory Filings" means all applications, registrations, licenses, permits, authorizations and approvals, including all non-clinical and clinical study authorization applications or notifications (including all INDs), and amendments and supplements to any of the foregoing, in each case related to the Product.

1.55         "Relief Indemnified Party" has the meaning set forth in Section 7.1.

1.56         "Royalty Payment" or "Royalty Payments" has the meaning set forth in Section 2.6(a).

1.57         "Royalty Term" has the meaning set forth in Section 2.6(c).

1.58         "SEC" has the meaning set forth in Section 8.3(b).

1.59         "Selling Party" has the meaning set forth in Section 1.43.

1.60         "Tax" or "Taxes" means any tax (including any income tax, franchise tax, capital gains tax, estimated tax, gross receipts tax, surtax, excise tax, transfer tax, sales tax, use tax, property tax, business tax, occupation tax, inventory tax, occupancy tax, withholding tax or payroll tax), documentary charges, recording fees, levy, assessment, tariff, impost, imposition, toll, duty (including any customs duty), deficiency or fee, and any related charge or amount (including any fine, penalty or interest), that is, has been or may in the future be (a) imposed, assessed or collected by or under the authority of any Governmental Authority, or (b) payable pursuant to any tax-sharing agreement or similar contract.

1.61         "Third Party" means, with respect to either Party, any Person other than such Party or an Affiliate of such Party.

1.62         "Third-Party Claim" has the meaning set in Section 7.3(a).

1.63         "Trade Secrets" means all rights in United States and foreign trade secrets and other confidential information that derives independent economic value, actual or potential, from not being generally known to, and not readily ascertainable without improper means by, other parties, in any format, whether tangible or intangible, which in each case is the subject of reasonable efforts to maintain its confidentiality. Trade Secrets include all rights in such confidential information that is contained in non-public unpublished applications for Patents.

1.64         "Transactions" has the meaning set forth in the Recitals of this Agreement.

1.65         "Transferred Assets" has the meaning set forth in Section 2.1.

1.66         "Transferred Claims" has the meaning set forth in Section 2.1(e).

1.67         "Transferred Contracts" means the contracts between NRx or any of its Affiliates and Third Parties that are exclusively related to the Product and are either assignable without the consent of the counterparty or where consent to assignment to Relief has been obtained from the counterparty, in each case as listed on Schedule 1.67.

1.68         "Transferred IP" means: (i) the United States patent application(s) relating exclusively to the Product set forth on Schedule 1.68 attached hereto, (ii) any other intellectual property (including, but not limited to, trademarks and licenses) related exclusively to the Product and set forth on Schedule 1.68; and (iii) NRx's license agreement with Stony Brook.

1.69         "Transferred Materials" means: (i) all inventory of Product, together with all inventory of the Compound and raw materials (such as API), work-in-progress, components, supplies, finished goods and other inventories used in the manufacture of the Product for development or use, or commercialization that is in the possession or control of NRx or its Affiliates as of the Execution Date (including any inventory or such other materials held by any licensees, contractors, or subcontractors of NRx or its Affiliates as of the Execution Date but only to the extent that NRx or one of its Affiliates has legal title to and the right to transfer such inventory or other materials as of the Execution Date), wherever held, (ii) reference standards of the Compound, and (iii) retention and stability samples. Schedule 1.69 attached hereto contains a correct and complete list of all inventory of Product and all inventory of Compound (including, in each case (a) held by NRx and its Affiliates, contractors and subcontractors as of the Execution Date, including the quantities and location where such inventory is held and whether NRx or its Affiliate, contractor or subcontractor has legal title to such inventory, and (b) shipped by NRx or its Affiliate, contractor or subcontractor prior to the Execution Date to physicians or investigators, and reasonably expected by NRx to be held by such physicians or investigators as of the Execution Date, including the quantities and location to which such inventory was shipped. For avoidance of doubt, inventory shipped to physicians or investigators under NRx's Right to Try Program shall be included on such schedule.

1.70         "Transferred Records" means the documents (or copies of such documents) that in each case are exclusively related to development, formulation, use, manufacture, or commercialization of the Product and are in the possession or control of NRx or its Affiliates as of the Execution Date (including any such documents in the possession of any licensees, contractors or subcontractors, including service providers (including data, records and information management companies, CMOs, CROs and CDMO’s of NRx or its Affiliates). For avoidance of doubt, this includes (i) NRx's IND for the Product, (ii) NRx's Regulatory Filings with the FDA or any other Regulatory Authority relating exclusively to the Product, including any IND or NDA filed for the Product, and any applications for Breakthrough-Therapy Designation or Emergency Use Authorization, (iii) NRx's written correspondence with the FDA or any other Regulatory Authority exclusively relating to the Product, (iv) all data from all clinical and pre-clinical trials and studies undertaken by NRx relating to the Product (including data from the TESCO/Active 3b trial previously run by the National Institutes of Health), (v) all CMC data and all stability data exclusively relating to the Product, and (vi) any written FTO analysis and prior art analysis performed exclusively relating to the Product. Copies of all Transferred Records have, or as of the Closing Date, shall have been placed in the data room.

1.71         "United States" means the United States of America and its territories and possessions (including the District of Columbia and Puerto Rico).

1.72         "Updated Disclosure Schedule" has the meaning set forth in Section 5.13.

1.73         "Valid Claim" means a claim of any Patent that covers the research, development, making, using, or selling of a Product, whose validity, enforceability, or patentability has not been affected by any of the following: (i) irretrievable lapse, abandonment, revocation, dedication to the public, or disclaimer; or (ii) a holding, finding, or decision of invalidity, unenforceability, or non-patentability by a court, governmental agency, national or regional patent office, or other appropriate body that has competent jurisdiction, such holding, finding, or decision being final and unappealable or un-appealed within the time allowed for appeal.

SECTION 2. Purchase and Sale OF ASSETS

2.1           Purchase and Sale of Assets. Subject to the terms and conditions of this Agreement, effective at the Closing, NRx on behalf of itself, NeuroRx, and its Affiliates hereby sells, conveys, assigns and transfers to Relief and Relief hereby purchases, acquires and accepts from NRx, free and clear of all Liens (other than Permitted Liens, if any), all of NRx's and its Affiliates’ right, title, and interest in, to and under the Transferred Assets, which assets include all of the assets currently held by NRx which were used by NRx in connection with its efforts to develop the Product.

As used herein, "Transferred Assets" mean the following assets ((a) through (e)) existing as of the Closing:

(a)           the Transferred Records, provided, however, that NRx may retain copies of all Transferred Records after the Closing for record-keeping purposes and to ensure compliance with applicable Law;

(b)           the Transferred Materials, provided, however, that Relief shall be solely responsible for all costs and expenses associated with transporting the Transferred Materials from the location where such Transferred Materials are located as of the Execution Date to the contract manufacturer that will hold the Transferred Materials on behalf of Relief following the Closing Date;

(c)           the Transferred Contracts, excluding, in each case, any and all rights, defenses, claims or causes of action (including warranty claims) of NRx or any of its Affiliates thereunder related to Excluded Assets or Excluded Liabilities;

(d)           the Transferred IP; and

(e)           all claims, counterclaims, defenses, causes of action, rights under express or implied warranties, rights of recovery, rights of set-off, rights of subrogation and all other rights of any kind against any Third Party, to the extent relating to any of the foregoing Transferred Assets, including all rights to sue and recover and retain damages, costs and attorneys’ fees for past, present and future infringement of any Transferred IP (collectively, "Transferred Claims"); provided, however, that, for the avoidance of doubt, the Transferred Claims shall in no event include any claims, counterclaims, defenses, causes of action, rights under express or implied warranties, rights of recovery, rights of set-off, rights of subrogation and all other rights that NRx or its Affiliates may have arising under the Settlement Agreement or this Agreement, any Ancillary Agreement or as a result of the consummation of the Transactions contemplated hereby.

2.2           Excluded Assets. Relief is not acquiring pursuant to this Agreement or any Ancillary Agreement, and NRx and its Affiliates shall retain, any and all right, title or interest in: (i) any assets, properties or rights of NRx or any of its Affiliates of any kind or nature other than the Transferred Assets or (ii) any rights, claims, counterclaims, defenses, causes of action, rights under express or implied warranties, rights of recovery, rights of set-off, rights of subrogation and all other rights of any kind or nature that NRx or its Affiliates may have that are not exclusively related to the Transferred Assets, this Agreement, any Ancillary Agreement, or the Settlement Agreement (collectively, the "Excluded Assets").

2.3           Assumed Liabilities. Effective at the Closing, Relief hereby assumes and agrees to bear, pay, perform, satisfy and discharge when due (all of the following being collectively referred to herein as the "Assumed Liabilities"):

(a)           all Liabilities arising on or after the Closing Date under the Regulatory Filings transferred and assigned to Relief hereunder;

(b)           all Liabilities arising on or after the Closing Date under the Transferred Contracts but only to the extent such Liabilities (i) do not arise from any breach, default, violation or failure to perform by NRx or any of its Affiliates of any provision under any Transferred Contract before the Closing Date, (ii) do not arise by reason of events or circumstances occurring prior to the Closing Date which with notice or lapse of time, would constitute or result in a breach of any Transferred Contract, (iii) if arising or relating to a circumstance in existence prior to the Closing Date, arise in accordance with the express terms of such Transferred Contracts, excluding any such Liabilities that relate to or arise from any failure to perform, improper performance, warranty or other breach, default or violation by NRx under any Transferred Contract before the Closing Date, (iv) are not Excluded Liabilities, and (v) represent solely the performance of post-Closing obligations that were not required to be performed under the Transferred Contracts prior to the Closing Date; and

(c)           all other Liabilities arising out of, relating to, or associated directly or indirectly with, Relief’s or its Affiliates’ or any of their licensees’, sublicensees’ or distributors’ ownership or use of the Compound, the Product or the Transferred Assets after the Closing Date.

2.4           Excluded Liabilities. Relief expressly does not assume and shall not be liable to bear, pay, perform, satisfy or discharge any Liability whatsoever of NRx or its Affiliates, other than the Assumed Liabilities (the "Excluded Liabilities"), and NRx shall retain and shall bear, pay, perform, satisfy and discharge all Excluded Liabilities.

2.5           Closing.

(a)           The consummation of the purchase and sale of the Transferred Assets and the assumption of the Assumed Liabilities in accordance with this Agreement (the "Closing") shall take place on such date as NRx and Relief agree upon in writing ("Closing Date"); provided that, subject to Section 6, the Closing shall occur no later than thirty (30) days after the Execution Date, unless otherwise agreed to in writing by the Parties. Unless otherwise agreed in writing by the Parties, the Closing shall be deemed to have occurred at 12:00 a.m., Eastern time, on the Closing Date, such that Relief shall be deemed the owner of the Transferred Assets on and after the Closing Date. All events which shall occur at the Closing shall be deemed to occur simultaneously. Further, NRx agrees from time to time, and without further consideration, to use Commercially Reasonable Efforts to execute all specific assignments, oaths, declarations, deeds or other instruments that are reasonably requested by Relief to transfer to Relief and vest in Relief the legal title to the Transferred Assets.

(b)           On the Closing Date, NRx shall transfer to Relief the tangible embodiments of the Transferred Assets (including (i) the Transferred IP, (ii) the Transferred Records, (iii) the Transferred Materials, provided that Relief shall be responsible for and shall pay and arrange for the transfer of all Transferred Materials from its present location to the contract manufacturer that will hold the Transferred Materials on behalf of Relief following the Closing, (iv) the Transferred Contracts, and (v) the Regulatory Filings. Further, on the Closing Date, NRx shall use Commercially Reasonable Efforts to notify any party that was materially and substantively involved with or worked with NRx in the development of the Product, was a counterparty with respect to the Transferred Contacts, or was a material advisor to NRx with respect to the Transferred IP, the Regulatory Filings or the Transferred Materials that such party is free to discuss their work with NRx as if Relief were NRx for this purpose, as such party sees fit in their sole discretion. A detailed list of all tangible embodiments of the Transferred Assets, the Transferred Contracts and the Regulatory Filings shall be contained in Schedule 2.5(b), which shall include a schedule as to the timing of each such delivery (other than as to the Transferred Materials for which Relief shall be responsible for transferring and delivery), and the third parties as to whom NRx has given permission to discuss their work with Relief.

(c)           Upon confirmation by the Parties that the Transferred Assets have been transferred to Relief as required by Schedule 2.5(b), the Parties shall close the Transactions and deliver the following documents (each of which shall have been executed and placed in escrow as of the Execution Date), at which time the Closing shall be completed:

(i)           NRx and Relief shall each deliver an executed counterpart Intellectual Property Assignment Agreement in the form attached hereto as Exhibit A;

(ii)          NRx and Relief shall each deliver an executed counterpart Assignment and Assumption Agreement in the form attached hereto as Exhibit B;

(iii)         NRx and Relief shall each deliver an executed counterpart Bill of Sale in the form attached hereto as Exhibit C;

(iv)         Each Party shall deliver a certificate executed by an authorized officer of the delivering Party, in his or her capacity as such, confirming the satisfaction of the conditions to Closing applicable to such Party as set forth in Section 6; and

(v)          Each Party shall deliver a certificate executed by an authorized officer of the delivering Party, in his or her capacity as such, confirming the accuracy of such Party’s representation and warranty regarding power and authority (Section 3.4, with respect to NRx, and Section 4.3, with respect to Relief), together with copies of such Party’s Articles of Incorporation, Bylaws and Board and shareholder (if required) resolutions evidencing such power and authority.

2.6           Royalty and Milestone Payments.

(a)           Relief shall pay royalties on aggregate Net Sales of all Products during the Royalty Term at the following rates (each, a "Royalty Payment," and, collectively, the "Royalty Payments"):

(i)           for sales of the Product in the United States for the treatment of COVID-19, [Redacted] of Net Sales;

(ii)          for sales of the Product in the United States for an indication other than COVID-19, [Redacted] of Net Sales; and

(iii)         for sales of any product containing the Compound (including the Product) for any indication, on a country-by-country basis in any country outside the United States, [Redacted] of Net Sales.

provided, however, that all Royalty Payments payable hereunder shall not exceed $30 million in the aggregate.

(b)           Relief shall pay milestone payments to NRx upon the occurrence of any of the following (each, a "Milestone Payment" and collectively, the "Milestone Payments"):

(i)           If the Product is commercially launched by Relief or any of its Affiliates or its or their respective licensees and sublicensees thereof for the treatment of COVID-19 in the United States, upon the first commercial sale, a one-time milestone payment of [Redacted];

(ii)          if the Product is commercially launched by Relief or any of its Affiliates or its or their respective licensees and sublicensees thereof for the treatment of COVID-19 in any country in Europe, upon the first commercial sale, a one-time milestone payment of [Redacted]; and

(iii)         if any product containing the Compound (including the Product) is approved or otherwise authorized for use for any indication other than COVID-19 in either the United States or in any country in Europe, a one-time milestone payment of [Redacted].

(c)           Royalty Payments will be payable with respect to all Products sold until the expiration of the last Valid Claim for the Product, including for this purpose Valid Claims for other products containing the Compound ("Royalty Term"). Relief shall use Commercially Reasonable Efforts to develop, market, and commercialize the Product; provided, however, that Relief shall have the sole and absolute discretion to select the indications for which it will seek to develop, market and commercialize the Product and shall not be obligated to develop, market, or commercialize the Product for any particular indication (including COVID-19).

(d)           All Royalty Payments shall be made in Dollars. All Royalty Payments for an accounting period computed in other currencies shall be converted into Dollars at the buying rate for bank transfers from such currency to Dollars as quoted by the head office of Citibank N.A., New York, at the close of banking on the last day of such accounting period (or the Business Day thereafter if such last day shall be a Sunday or other non-business day). Within forty-five (45) days after the last day of each Calendar Half Year, Relief shall provide to NRx a report setting out: (i) aggregate gross sales of Product in the relevant Half Year, listed by Product and showing the quantities, selling price and country of sale; (ii) aggregate Net Sales of Products in the relevant Half Year, listed by Product and country of sale, showing the quantities and selling price and all deductions; (iii) Calendar Year-to-date aggregate Net Sales of Products; (iv) the amount of the Royalty Payment due for the relevant Half Year, and (v) identification by type, number, quantity, and description of each Product used, leased, sold or otherwise transferred, by or for Relief or any Affiliate during the Half Year and which is exempt from royalty and the reason such exemption applies. In the event no Royalty Payments are due, Relief’s report shall so state. Relief’s Half Year reports shall be certified by the Chief Financial Officer of Relief or his or her designee. Simultaneously with the delivery of each such report, Relief shall pay to NRx the total Royalty Payments due under Section 2.6(a) for the Half Year covered by such report. All Royalty Payments under this Agreement will be irrevocable, non-refundable, non-recoupable, and non-creditable. All Royalty Payments and Milestone Payments shall be treated as amounts paid by Relief in consideration for the sale and transfer of the Transferred Assets.

2.7           Withholding. Relief shall be entitled to deduct and withhold all Taxes that Relief is required by applicable Law to deduct and withhold. To the extent that such amounts are withheld and timely paid to the appropriate Governmental Authority and Relief provides NRx with a timely report of such withholding, all such withheld amounts shall be treated as delivered to NRx hereunder. Relief will promptly pay such withholding to the proper Governmental Authority and will furnish NRx with copies of any tax certificates or other documentation evidencing such withholding after remittance. The Parties agree to cooperate with one another and use reasonable efforts to avoid or reduce tax withholding or similar obligations in respect of any payment made by Relief to NRx hereunder. Notwithstanding the foregoing, if NRx is entitled under any applicable Law to a reduction of rate of, or elimination of, applicable withholding amounts, it may deliver to Relief or the appropriate Governmental Authority (with the assistance of Relief) the prescribed forms necessary to reduce the applicable rate of withholding or to relieve Relief of its obligation to withhold such amount and Relief shall apply the reduced rate of withholding or dispense with withholding, as the case may be.

2.8           Late Payments. Relief shall pay interest on any overdue payments from the due date until the date of payment at an annual rate of one and one-half percent (1.5%) per month or the maximum rate allowed by applicable Law, whichever is less.

SECTION 3. Representations and Warranties of NRx

NRx hereby represents and warrants to Relief as of (i) the Execution Date, subject to any exceptions listed on the Disclosure Schedule specifically identifying the relevant subparagraph hereof, and (ii) the Closing Date, subject to any exceptions listed on the Updated Disclosure Schedule specifically identifying the relevant subparagraph hereof, and acknowledges that Relief is entering into this Agreement in reliance thereon, as follows:

3.1           Full Disclosure. No representation or warranty by NRx in this Agreement and no statement contained in the Disclosure Schedule or any certificate or other document furnished or to be furnished by NRx to Relief pursuant to this Agreement contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements contained therein, in light of the circumstances in which they are made, not misleading.

3.2           Organization and Standing. NRx Pharma and NeuroRx are corporations duly organized, validly existing and in good standing under the laws of the State of Delaware.

3.3           Ownership; Liens; Sufficiency of Assets. NRx has good and marketable title or otherwise has transferrable rights, licenses or interests to the Transferred Assets (subject to Permitted Liens). No Affiliate of NRx (including for this purpose any current or former officer or director of NRx Pharma or NeuroRx) has any right, title or interest in or to any Transferred Asset. The Transferred Assets are not subject to any Liens (other than Permitted Liens) and, subject to Relief’s and its Affiliates’ compliance with applicable Laws (including Laws concerning intellectual property rights and export control) and except as set forth in and subject to Relief’s and its Affiliates’ compliance with the Transferred Contracts and any consents required thereunder, there are no restrictions or limitations on the assignments, transfer, or sale of the Transferred Assets to Relief. The Transferred Assets constitute all of the material tangible and intangible assets owned or licensed by NRx and its Affiliates that are exclusively related to the Product. None of the assets that would be Transferred Assets if they were held by NRx on the Execution Date have previously been transferred to any Affiliate of NRx (including for this purpose any current or former officer or director of NRx Pharma or NeuroRx), and no assets that would be Transferred Assets will be transferred to any Affiliate of NRx (including for this purpose any current or former officer or director of NRx Pharma or NeuroRx) between the Execution Date and the Closing Date.

3.4           Power and Authority. (a) NRx has all requisite corporate power and authority to execute, deliver and perform this Agreement and to consummate the Transactions, (b) the execution, delivery and performance of this Agreement by NRx does not, and the consummation of the Transactions will not, violate any provisions of NRx's or its Affiliates’ organizational documents or bylaws, or, violate any provisions of any Law applicable to NRx or its Affiliates, or any agreement (assuming all required consents to assignment are obtained by Relief), instrument, order, judgment or decree to which NRx or any of its Affiliates is a party or by which NRx or any of its Affiliates is bound, and (c) there are no claims by creditors of NRx or any of its Affiliates affecting the Transferred Assets or the Product or the ability of NRx to consummate the Transactions, except in each case as would not reasonably be expected to have a Material Adverse Effect on NRx or materially and adversely affect NRx's ability to consummate the Transactions.

3.5           Corporate Action; Binding Effect. (a) NRx has duly and properly taken the actions required by Law, its organizational documents or otherwise, to authorize the execution, delivery and performance of this Agreement and the consummation of the Transactions, and (b) when duly executed and delivered by NRx, this Agreement will constitute, legal, valid and binding obligations of NRx enforceable against it in accordance with its terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium or similar Laws of general application affecting or relating to the enforcement of creditors’ rights generally, and subject to equitable principles of general applicability, whether considered in a proceeding at Law or in equity (the "Bankruptcy, Equity and Indemnity Exception").

3.6           Intellectual Property.

(a)           NRx has no Knowledge of any Patent rights of any of its Affiliates or any Third Parties that would be infringed by the commercial development, sale, or distribution of the Product.

(b)           Schedule 1.68 contains a correct, current, and complete list of all patent applications included in the Transferred IP, specifying as to each such patent: (i) the title, (ii) the patent application serial number, and (iii) the filing date. The Patents included in the Transferred IP listed on Schedule 1.68 are the only patent applications made by NRx and its Affiliates anywhere in the world solely with respect to the Product owned or controlled by NRx and its Affiliates as of the Execution Date that would be infringed by the development, use, manufacture, or sale of the Product as it exists on the Execution Date.

(c)           Except as was disputed in the Litigations, NRx is the sole and exclusive owner of the Transferred IP and has the right to assign the Transferred IP to Relief free and clear of all Liens (other than Permitted Liens). Other than the Transferred IP listed on Schedule 1.68, there are no Patents owned or controlled by NRx or its Affiliates, and neither NRx nor any of its Affiliates has filed any Patents on or prior to the Execution Date, that (i) contain any claims directed to inventions within any Competing Product or that otherwise claim, disclose or describe any Competing Product Know-How, or (ii) would be infringed by the use of the Product by Relief.

(d)           The execution, delivery, or performance of this Agreement, and the consummation of the Transactions, will not result in the material loss or impairment of or payment of any additional amounts (other than amounts payable as part of the Assumed Liabilities) with respect to Relief’s right to own or use the Transferred IP (assuming consent to assignment is obtained from the contract counterparties where applicable). This representation does not apply to the payment of recordation fees to the USPTO and the intellectual property rights offices of other Governmental Authorities with respect to the Transferred IP.

(e)           NRx has no Knowledge of any information, facts or circumstances that would reasonably be expected to be a valid basis for a challenge to, or that otherwise would reasonably be expected to have a Material Adverse Effect on, the ownership, use, patentability, enforceability or validity of the Transferred IP, other than office actions in the course of prosecution of the Transferred IP. Except as disclosed by the patent applications included in the Transferred IP and for office actions in the course of prosecution of the Transferred IP, none of the Transferred IP is subject to any action or order of any Governmental Authorities restricting the conduct of NRx to accommodate or avoid intellectual property rights of a Third Party.

(f)            Except as set forth in Section 3.6(f) of the Disclosure Schedule or alleged in the Litigations:

(i)           there has not been, and currently there is no, pending or, to NRx's Knowledge, threatened written action, proceeding, or other written claim contesting the ownership, use, patentability, enforceability, validity, or right of NRx to exercise any of the Transferred IP other than office actions in the course of prosecution of the Transferred IP;

(ii)          there has not been, and currently there is no pending or, to NRx's Knowledge, threatened written action or proceeding, or other written claim against NRx alleging actual or potential infringement, misappropriation or other violation (directly or indirectly, via contribution or inducement) of a Third Party’s patents, trademarks, service marks, trade names, copyrights, Trade Secrets or other proprietary rights, due to the use or development, of the Transferred IP or the Product;

(iii)         to the Knowledge of NRx, there is no legitimate basis for any such claims in (i) and (ii);

(iv)         to the Knowledge of NRx: (i) NRx and its Affiliates have not in the past three (3) years infringed (directly, contributorily, by inducement, or otherwise), misappropriated, or otherwise violated any Patents, Know-How, or other intellectual property rights of any Third Party or engaged in unfair competition; in each case solely in connection with the creation, discovery, acquisition, development, manufacture, or use of the Product, or any Transferred IP in a manner that has or would reasonably be expected to result in a material liability to NRx and its Affiliates, taken as a whole; and (ii) no Transferred IP or method or process of manufacturing or use of the Product by NRx or its Affiliates prior to the Execution Date infringes, violates, or makes unlawful use of any Patents or other intellectual property rights misappropriated from, any Third Party in a manner that has or would reasonably be expected to result in a material liability to NRx and its Affiliates, taken as a whole.

(v)          there has not been, and currently there is no pending, or to NRx's Knowledge threatened, written action, proceeding, or other written claim that any NRx representative (including its current and former officers, directors and employees) or consultant or contractor of NRx or its Affiliates ("NRx Representative") has or claims any ownership interest in any of the Transferred IP, and to the Knowledge of NRx, there is no legitimate basis for any such assertions or claims;

(vi)         NRx and its Affiliates have not received any written notice or written offer from any Third Party offering a license under any Third-Party patents for the purpose of avoiding a claim that such patents would be infringed by the use, manufacture, sale, offering for sale, or importation of the Product or any Transferred IP.

(g)           To NRx's Knowledge, and except as alleged in the Litigations, no Person has infringed or misappropriated in the past or is currently infringing or misappropriating any Transferred IP.

(h)           NRx and its Affiliates have taken security measures reasonable under the circumstances to protect the secrecy and confidentiality of all Know-How that NRx or any of its Affiliates maintains as Trade Secrets or otherwise treats as confidential or proprietary ("Know-How Confidential Information"), as determined by NRx and its Affiliates in its and their reasonable business judgment and except where the failure would not reasonably be expected to have a Material Adverse Effect. No NRx Representative or consultant or contractor of NRx or its Affiliates with access to any Know-How Confidential Information has any right, license, claim or interest whatsoever in or with respect to any Transferred IP.

(i)            NRx has a policy that requires employees, officers, consultants, contractors and other Persons who developed for or on behalf of NRx or any of its Affiliates any part of any Transferred IP to enter into a written agreement that assigns to NRx or any of its Affiliates ownership of all intellectual property developed by such person in the scope of such person’s employment with or engagement by NRx or any of its Affiliates (other than intellectual property excluded by operation of California Labor Code section 2870 or any similar law and non-assignable moral rights). NRx has entered into such agreements with all such persons according to this policy.

(j)            No current or former NRx employee, officer, director, or Affiliate owns any inventions relating to the development of the Product made prior to or outside the scope of their relationship with NRx which has not been or will not be assigned to NRx or any of its Affiliates with respect to the Transferred IP.

(k)           Except as alleged in the Litigations, NRx has not received any written notice that any employee of NRx (i) has been or is in material violation of any term or covenant of any employment contract, patent disclosure agreement, invention assignment agreement, nondisclosure agreement, noncompetition agreement or any other similar contract with any Third Party by virtue of such employee being employed by, or performing services for NRx or using trade secrets or proprietary information of any Third Party without permission; or (ii) has developed any technology underlying the Transferred IP that is subject to any contract under which such employee has assigned or otherwise granted to any Third Party any rights (including intellectual property rights) in or to such technology.

3.7           Regulatory Matters.

(a)           NRx and its Affiliates have complied, and are now complying, in all material respects with all applicable Laws applicable to NRx's or its Affiliates’ (as applicable) ownership or use and of the Transferred Assets and Product. NRx has delivered or will deliver on or prior to the Closing Date to Relief, solely with respect to the Product, copies of any written material reports in NRx's and its Affiliates’ possession and control as of or before the Closing Date of inspectional observations, establishment inspection reports, untitled letters, warning letters and any other material documents received by NRx or any of its Affiliates from a Governmental Authority relating exclusively to the Product, in each case that arise from a lack of compliance, in any material respect, with any applicable Laws. All CMC data, stability reports, manufacturing batch records and CMC related regulatory filings have, or as of the Closing Date, shall have been placed in the data room.

(b)           NRx and its Affiliates have not, and, to NRx's Knowledge, NRx's current and former employees, officers, directors, or Affiliates have not made, in each case solely with respect to the Product, any statement or failed to make any statement, that (in any such case) establishes a reasonable basis for the FDA to invoke its Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities Policy. In relation to the Product, NRx and its Affiliates are not the subject of any pending or, to NRx's Knowledge, threatened investigation by the FDA pursuant to its Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities Policy. To NRx's Knowledge, there are no FDA commitments with respect to the Product and the Transferred Assets.

(c)           NRx and its Affiliates are not subject to any pending or, to NRx's Knowledge, threatened enforcement, regulatory or administrative proceedings against NRx or any of its Affiliates with respect to any alleged or actual violation by NRx or its Affiliates of any applicable Law or other requirement of any Governmental Authority relating to the Product, including under the FDCA. NRx has no Knowledge of any existing facts in any jurisdiction that would lead to any future enforcement, regulatory, or administrative actions that would have a Material Adverse Effect on the Product, the Transferred Assets, or the Transactions.

(d)           NRx and its Affiliates have not been debarred or suspended under 21 U.S.C. §335(a) or (b), are not the subject of a conviction described in Section 306 of the FDCA, have not been excluded from a federal health care program, debarred from federal contracting, convicted of or pled nolo contendere to any felony, or to any federal or state legal violation (including misdemeanors) relating to prescription drug products or fraud, and are not subject to any similar sanction of other Regulatory Authorities outside of the United States ("Debarred/Excluded") and, to NRx's Knowledge, none of the NRx Representatives (while employed by NRx) involved in the use of the Product has been Debarred/Excluded.

(e)           NRx has made available to Relief copies of all material information and data in NRx's and its Affiliates’ possession or control as of the Execution Date, or the Closing Date, as applicable, specifically and exclusively relating to the safety of the Product, including written summaries in NRx's and its Affiliates’ possession or control of complaints and notices of alleged Product defects or adverse reactions resulting from administration of the Product.

3.8           Legal Proceedings. Except for the Litigations, there is no pending Legal Proceeding against NRx or its Affiliates, and, to NRx's Knowledge, except as alleged in the Litigations, no Person has threatened to commence any Legal Proceeding against NRx or its Affiliates: (a) that involves the Transferred Assets or the Product and would reasonably be expected to have a Material Adverse Effect on the Transferred Assets; or (b) that challenges, or that may have the effect of preventing, delaying, making illegal or otherwise materially interfering with, the Transactions. To NRx's Knowledge, no event has occurred that would give rise to any such Legal Proceeding. NRx has made available or will make available to Relief copies of all filed complaints and claims related to the Product by NRx and its Affiliates or the ownership or use of the Transferred Assets by NRx and its Affiliates that are in the possession of NRx or its Affiliates.

3.9           Transferred Contracts.

(a)           Schedule 1.67 sets forth a correct, current, and complete list of all material contracts between NRx or its Affiliates and Third Parties that are exclusively related to the Product. NRx has made available to Relief unredacted copies of all such contracts where doing so would not be in violation of such contract or other obligation owed to the Third Party. Schedule 1.67 lists which contracts are Transferred Contracts. All material contracts exclusively related to the Product that are not designated as Transferred Contracts on Schedule 1.67 shall be cancelled by NRx. Copies of all material contracts related to the Product (whether or not a Transferred Contract) have, or as of the Closing Date, shall been made available in the data room.

(b)           (i) Each Transferred Contract is valid and binding on NRx and, to NRx's Knowledge, the counterparty thereto, subject to the Bankruptcy, Equity and Indemnity Exception, (ii) except as would not reasonably be expected to have any Material Adverse Effect, NRx is not, and to NRx's Knowledge no counterparty to any Transferred Contract is, in material breach in the performance, observance or fulfillment of any material obligation or covenant contained in any Transferred Contract and, to NRx's Knowledge, no event has occurred, that with the giving of notice or lapse of time or both, would constitute a material breach thereunder, and (iii) NRx has not received: (A) any written notice from any counterparty to any Transferred Contract at any time during the past twelve (12) months regarding NRx's material violation of, material default under, or such counterparty’s intention to cancel or make any material change to any Transferred Contract, (B) any communication from any counterparty to any Transferred Contract that (1) it has materially changed, modified, amended or reduced, or is reasonably likely to materially change, modify, amend or reduce, its business relationship with NRx in a manner that is, or would be, materially adverse to NRx or (2) it will fail to perform, or is reasonably likely to fail to perform, its obligations under any Transferred Contract with NRx in any manner that is, or is reasonably likely to be, materially adverse in any material respect to NRx.

(c)           To NRx's Knowledge, there exists no legitimate basis with respect to NRx or with respect to any counterparty to a Transferred Contract, which, with the giving of notice or the lapse of time would reasonably be expected to give such counterparty the right to accelerate the maturity or performance of any obligation of NRx under any Transferred Contract, or the right to cancel, terminate or modify any Transferred Contract. NRx has not received any written, or to NRx's Knowledge, any oral request for indemnification pursuant to any Transferred Contract to which NRx is party.

3.10         Solvency. No Governmental Authority order has been made or petition presented, or resolution passed for the winding-up or liquidation of NRx Pharma or NeuroRx and there is not outstanding: (a) any petition or Governmental Authority order for the winding-up of NRx Pharma or NeuroRx; (b) any appointment of a receiver over the whole or part of the undertaking or assets of NRx Pharma or NeuroRx; (c) any petition or Governmental Authority order for administration of NRx Pharma or NeuroRx; (d) any voluntary arrangement between NRx Pharma or NeuroRx and their creditors; (e) any distress or execution or other process levied in respect of NRx Pharma or NeuroRx which remains undischarged; or (f) any unfulfilled or unsatisfied Governmental Authority order against NRx Pharma or NeuroRx

3.11         Brokers and Finders. No broker, finder or investment banker is entitled to any brokerage or finder’s fee in connection with the Transactions based upon arrangements made by or on behalf of NRx.

SECTION 4. Representations and Warranties of Relief

Relief hereby represents and warrants to NRx as of the Closing Date as follows:

4.1           Full Disclosure. No representation or warranty by Relief in this Agreement or any certificate or other document furnished or to be furnished by Relief to NRx pursuant to this Agreement contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements contained therein, in light of the circumstances in which they are made, not misleading.

4.2           Organization and Standing. Holding and International are corporations duly organized, validly existing and in good standing under the laws of the Country of Switzerland, Canton of Geneva.

4.3           Power and Authority. (a) Relief has all requisite corporate power and authority to execute, deliver and perform this Agreement and to consummate the Transactions, and (b) the execution, delivery and performance of this Agreement by Relief does not, and the consummation of the Transactions will not, violate any provisions of Relief’s organizational documents or bylaws, or, to Relief’s Knowledge, violate any provisions of any Law applicable to Relief, or any agreement, instrument, order, judgment or decree to which Relief is a party or by which Relief is bound, except in each case as would not reasonably be expected to have a Material Adverse Effect on Relief or materially and adversely affect Relief’s ability to consummate the Transactions.

4.4           Corporate Action; Binding Effect. (a) Relief has duly and properly taken all action required by Law, its organizational documents or otherwise, to authorize the execution, delivery and performance of this Agreement and the consummation of the Transactions, and (b) when duly executed and delivered by Relief, this Agreement will constitute, legal, valid and binding obligations of Relief enforceable against it in accordance with its terms, subject to the Bankruptcy, Equity and Indemnity Exception.

4.5           Legal Proceedings. Except for the Litigations and except as set forth in Schedule 4.5, there is no pending Legal Proceeding against Relief, and, to Relief’s Knowledge, no Person has threatened to commence any Legal Proceeding against Relief: (a) that would reasonably be expected to have a Material Adverse Effect on the Product or otherwise on Relief’s ability to perform its obligations under this Agreement; or (b) that challenges, or that may have the effect of preventing, delaying, making illegal or otherwise interfering with, the Transactions.

4.6           Not Debarred. Relief has not been debarred or suspended under 21 U.S.C. §335(a) or (b), is not the subject of a conviction described in Section 306 of the FDCA, has not been excluded from a federal health care program, debarred from federal contracting, convicted of or pled nolo contendere to any felony, or to any federal or state legal violation (including misdemeanors) relating to prescription drug products or fraud, and is not subject to any similar sanction of other Regulatory Authorities outside of the United States.

4.7           Solvency. No Governmental Authority order has been made or petition presented, or resolution passed for the winding-up or liquidation of Relief and there is not outstanding: (a) any petition or Governmental Authority order for the winding-up of Relief; (b) any appointment of a receiver over the whole or part of the undertaking or assets of Relief; (c) any petition or Governmental Authority order for administration of Relief; (d) any voluntary arrangement between Relief and its creditors; (e) any distress or execution or other process levied in respect of Relief which remains undischarged; or (f) any unfulfilled or unsatisfied Governmental Authority order against Relief.

4.8           Independent Investigation. Relief, in making the decision to acquire the Transferred Assets, has relied upon an independent investigation of the Transferred Assets and has not relied upon any information or representations made by any third parties or upon any oral or written representations or assurances from NRx, it Affiliates, officers, directors or employees or any other representatives or agents of NRx, other than as set forth in this Agreement. Relief has had an opportunity to ask questions of, and receive answers from the NRx’s officers and directors concerning NRx, the Product, and the Transferred Assets. Relief confirms that all documents that it has requested have been made available and that it has been supplied with all of the additional information concerning this purchase of the Transferred Assets which it has requested.

4.9           Brokers and Finders. No broker, finder or investment banker is entitled to any brokerage or finder’s fee in connection with the Transactions based upon arrangements made by or on behalf of Relief.

SECTION 5. Covenants of the Parties

5.1           Pre-Closing Period. During the period from the Execution Date through the Closing Date (the "Pre-Closing Period"), NRx will, after receiving reasonable advance written notice from Relief, give Relief reasonable access (during normal business hours) to NRx's books and records relating solely and exclusively to the Transferred Assets, and will provide Relief with such information in the possession or control of NRx and its Affiliates solely and exclusively regarding the Transferred Assets as Relief may reasonably request, for the purposes of enabling Relief: (a) to further investigate, at Relief's sole expense, the Transferred Assets; and (b) to verify the accuracy of the representations and warranties set forth in Section 3; provided that such access shall not interfere with NRx's normal business and operations. All of the books, records and other information to which Relief is provided access pursuant to this Section 5.1 shall be treated as "Confidential Information" of NRx until the Closing. Notwithstanding anything to the contrary in this Agreement, NRx shall not be required to provide access to or disclose to Relief any of the foregoing information during the Pre-Closing Period if: (i) upon the advice of counsel, such access or disclosure would jeopardize attorney-client, work product or similar privilege of NRx or contravene any (A) applicable Laws, (B) order of a Governmental Authority of competent jurisdiction or (C) obligations of confidentiality to Third Parties (whether contractual or otherwise) (provided that, in the case of the foregoing clause (i), NRx will use Commercially Reasonable Efforts to find a suitable alternative to disclose information in such a way that such disclosure does not violate any such applicable Law, order or confidentiality obligations or jeopardize privilege); or (ii) such access or disclosure would disclose a Trade Secret.

5.2           Ordinary Course. Except as explicitly permitted by this Agreement or as otherwise approved by Relief in writing in advance, during the Pre-Closing Period:

(a)           NRx will: (i) operate its business with respect to the Product in the ordinary course and consistent with past practices; (ii) comply with all applicable Laws applicable to its business; and (iii) use Commercially Reasonable Efforts to maintain good relations with the counterparties to the Transferred Contracts;

(b)           NRx will not (i) sell, license, transfer, assign, license, discard, destroy, dispose of or create any Liens (other than Permitted Liens) in the Transferred Assets, or enter into any material agreement or undertake any new obligation with any Person with respect to the Transferred Assets; or (i) terminate or amend any of the Transferred Contracts other than as required by the terms of any such Transferred Contracts;

(c)           NRx will use Commercially Reasonable Efforts to defend any challenge or opposition relating to the Transferred Patents, which challenge, or opposition shall have, or shall be reasonably likely to have, a Material Adverse Effect;

(d)           promptly after obtaining knowledge thereof, NRx shall notify Relief of (i) the occurrence or non-occurrence of any fact or event which causes or would be reasonably likely to cause (A) any representation or warranty of NRx contained in this Agreement to be untrue or inaccurate in any material respect or (B) any covenant, condition or agreement of NRx in this Agreement not to be complied with or satisfied in any material respect, and (ii) any failure of NRx to comply with or satisfy any covenant, condition or agreement to be complied with or satisfied by it hereunder; provided that no such notification shall affect the representations or warranties of NRx or Relief or Relief's right to rely thereon, or the conditions to the obligations of Relief hereunder. NRx shall give prompt notice in writing to Relief of any written notice or other communication from any Person alleging that the Consent of such Person is or may be required to be obtained by NRx in connection with the Transactions; and

(e)           NRx and its Affiliates will continue to enforce all agreements protecting Know How and Confidential Information consistent with past practices to the extent such agreements are not otherwise transferred to Relief pursuant to this Agreement.

5.3           Cooperation; Transfer. After the Closing Date, NRx and Relief shall each cooperate with the other Party and its employees, legal counsel, accountants and other representatives and advisers in connection with the steps reasonably required to be taken as part of their respective obligations under this Agreement; and each of them shall, from time to time after the Closing Date, upon the reasonable written request of the other, execute, acknowledge and deliver, or use Commercially Reasonable Efforts to cause to be executed, acknowledged and delivered, all such further acts, deeds, assignments, transfers, conveyances, receipts, acknowledgments, acceptances and assurances as may be reasonably required (without incurring unreimbursed expense) in order to complete the Transactions on the terms and subject to the conditions set forth herein. Further, NRx agrees to continue to make available to Relief for 60 days following the Closing Date the data room and to allow Relief during such 60 day period to download full copies of everything contained in the data room.

5.4           Governmental Filings. After the Execution Date, NRx and Relief each agree to prepare and file whatever filings, requests or applications that are required to be filed with any Governmental Authority in order to consummate the Transactions and to cooperate with one another as reasonably necessary to accomplish the foregoing. Subject to Section 5.13, each Party shall bear its own costs of such filings, requests, or applications.

5.5           Regulatory Filings. Relief acknowledges and agrees that after transfer to Relief of all Regulatory Filings included in the Transferred Assets, it will have sole responsibility for all regulatory reporting and Regulatory Filing maintenance obligations, including, for the Product and the Transferred Assets, adverse event reporting. Until the transfer of such Regulatory Filings from NRx to Relief is completed, Relief and NRx shall give prompt written notice to the other Party upon becoming aware of any action by, or notification which it receives (directly or indirectly) from, any Governmental Authority (together with copies of correspondence related thereto), which raises any material concerns regarding the safety or efficacy of the Product, or indicates or suggests a potential material liability for either Party to Third Parties arising in connection with the Product.

5.6           Non-Competition. From the Closing Date until the later of (a) expiration of the Royalty Term, or (b) December 31, 2035 (the "Non-Competition Term"), NRx and its Affiliates shall not, directly or indirectly, either on its or their own or with or through any other Person, research, develop, manufacture, commercialize, distribute, use or otherwise exploit any Competing Product in the Field anywhere in the world without the prior written consent of Relief, which consent may be granted or withheld in Relief’s sole discretion. Further, if Javitt, directly or indirectly, attempts to develop the Compound (including the Product) in violation of this Section 5.6, NRx covenants that it will not assist Javitt in any way, whether directly or indirectly in his activities which are in violation of this Section 5.6.

5.7           Patents. After the Closing Date, NRx shall not, itself or through an Affiliate or Third Party, file any Patent that claims or covers, the development, use, manufacture, or commercialization of the Product without first discussing such proposed Patent with Relief and obtaining Relief’s prior written consent to file such Patent.

5.8           Insurance.¹

¹Relief requests that NRx continue to carry products liability insurance coverage for patients dosed with the Product in connection with NRx's clinical trials of the Product or in connection with NRx's Right to Try program for a year following the Closing Date.

5.9           Reasonableness of Covenants. NRx acknowledges that Relief will invest substantial time and money to acquire and exploit the Transferred Assets, and the covenants set forth in Sections 5.6, 5.7 and 8.4 are a material part of the agreement between the Parties, are an integral part of the obligations of NRx hereunder, are supported by good and adequate consideration, and are reasonable and necessary to protect the legitimate business interests of Relief, and Relief would not consummate the Transactions unless the covenants set forth in such Sections were in full force and effect and constituted a binding and enforceable contract of NRx. NRx further acknowledges that the duration and geographic territory contained in Section 5.6 are reasonable in all respects and necessary to protect the value of the Transferred Assets and that, without such protection, Relief’s or any of its Affiliates’ competitive advantage would be adversely affected. Notwithstanding any other provision of this Agreement, the Parties agree that: (a) the covenants in Sections 5.6, 5.7 and 8.4 are severable and separate, and the unenforceability of any specific covenant will not affect the continuing validity and enforceability of any other covenant; and (b) if any court of competent jurisdiction determines that any of the scope, time or territorial restrictions set forth in Sections 5.6, 5.7 or 8.4 are unreasonable and therefore unenforceable, then the Parties agree that such provision will be enforced to the fullest extent that the court deems reasonable and this Agreement will thereby be reformed.

5.10         Audit. After the Closing, Relief shall keep, and shall require its Affiliates to keep, complete and correct books and records of Net Sales of Products in a manner compliant with IFRS and in sufficient detail to calculate Net Sales and all Royalty Payments payable hereunder. Relief shall maintain, and shall require its Affiliates to maintain, all such records for at least three (3) years after the Royalty Term. NRx may, once every Calendar Year and within 24 months after the end of the Royalty Term, upon reasonable (at least thirty (30) days’) prior written notice to Relief, conduct an audit of such books and records through an independent public accounting firm selected by NRx and reasonably acceptable to Relief. Such accountant shall have access, during regular business hours, to examine and inspect such books and records for the sole purpose of inspecting and confirming Net Sales and the Royalty Payments payable by Relief hereunder and that Net Sales was determined and calculated in accordance with IFRS. The accounting firm shall report to the Parties whether the Net Sales determination and calculation and Royalty Payments are correct and whether Net Sales was determined and calculated in accordance with IFRS and the details concerning any discrepancies. Any underpayments shall be paid by Relief within thirty (30) days of notification of the results of such audit. Any overpayments shall be credited against amounts payable by Relief in subsequent payment periods. If any such audit discloses an inaccuracy reflecting an under-reporting or underpayment of greater than three percent (3%) for the period of the audit report, then Relief also shall reimburse to NRx all costs and expenses incurred for such audit, within thirty (30) days of such audit; otherwise, the costs and expenses of such audit shall be paid by NRx. Any information received by NRx or its accounting firm under this Section 5.10 shall be subject to the confidentiality provisions of this Agreement.

5.11         Right to Try Program. Upon the Closing, NRx shall cease, and shall cause its Affiliates and their respective licensees, sublicensees and distributors to cease, all sales and distribution of the Product for compassionate use in the United States, including distribution of the Product under NRx's Right to Try Program. Subject to applicable regulatory requirements, Relief shall use its Commercially Reasonable Efforts to continue NRx's existing Right to Try Program for at least two (2) years after the Closing Date.

5.12         Updated Disclosure Schedule. At least three (3) Business Days prior to the Closing Date, NRx shall deliver to Relief an updated schedule setting forth any matter arising or occurring after the Execution Date that NRx determines (a) would have been required to be set forth or described in the Disclosure Schedule if such matter existed or occurred at or prior to the Execution Date, or (b) is necessary to correct any information in the Disclosure Schedule (the "Updated Disclosure Schedule"). The Updated Disclosure Schedule shall include all disclosure necessary to make the representations and warranties of NRx set forth in this Agreement true and correct in all material respects as though made as of the date of the Updated Disclosure Schedule (except that the accuracy of representations and warranties that by their terms speak as of a specified date will be determined as of such specified date); provided, that such disclosure shall consist solely of information regarding circumstances, facts, events or conditions that have arisen, occurred or come into existence after the Execution Date. Notwithstanding anything to the contrary herein, the Updated Disclosure Schedule (i) may only reflect changes necessary to disclose events or occurrences that occur after the Execution Date and (ii) shall not change the nature or scope of the applicable representations and warranties by effectively amending or modifying the language contained in such representations and warranties as opposed to merely listing exceptions thereto. The Updated Disclosure Schedule shall be in substantially the form of the Disclosure Schedule. Any amendment or supplement included in the Updated Disclosure Schedule shall not cure any breach or inaccuracy of any representation or warranty made as of the Execution Date; rather, such disclosures shall solely be deemed to modify and qualify any applicable representations and warranties as of the date of the Updated Disclosure Schedule; provided that, with respect to any information disclosed in the Updated Disclosure Schedule, if Relief shall consummate the Transactions at the Closing in accordance with this Agreement, Relief shall have irrevocably waived any right to assert after Closing that the failure of NRx to disclose any such information disclosed in the Updated Disclosure Schedule in the Disclosure Schedule constituted a breach by NRx of any representation or warranty and to make any indemnification claim pursuant to this Agreement in respect of such breach.

5.13         Transfer Taxes. All sales, use, transfer, stamp, registration, documentary, conveyance, recording, or other taxes required to consummate the Transactions (other than value added, franchise, or income taxes, or any taxes imposed by any Governmental Authority other than the United States) ("Transfer Taxes") shall be paid equally by NRx and Relief, and NRx and Relief will be responsible for bearing and paying fifty percent (50%) of any and all Transfer Taxes that may become payable in connection with the sale and purchase of, payment for, delivery of, or transfer of title to the Transferred Assets to Relief pursuant to this Agreement. Each Party shall file all necessary tax returns and other documentation required to be filed by it under applicable Law with respect to all Transfer Taxes, and, if required by applicable Law, Relief and NRx, if applicable, will join in the execution of any such tax returns and other documentation. Relief and NRx shall cooperate in providing each other with any appropriate resale exemption certifications and other similar documentation required to obtain any exemption from (or reduction in) Transfer Taxes and shall cooperate in taking any Commercially Reasonable Efforts to minimize liability for Transfer Taxes.

SECTION 6. Conditions to Closing; Termination

6.1           Conditions to Relief’s Performance. The obligation of Relief to complete the Closing of the Transactions is subject to the satisfaction (or written waiver by Relief), on or prior to the Closing Date, of each of the following conditions:

(a)           NRx shall have performed in all material respects all covenants and obligations required by this Agreement to be performed by NRx on or prior to the Closing Date;

(b)           NRx's representations and warranties set forth in Section 3 shall be true and correct in all material respects (except for such representations and warranties that are qualified by their terms by a reference to "Material Adverse Effect," which representations and warranties as so qualified shall be true and correct in all respects) as of the Closing Date;

(c)           All filings with and consents of any Governmental Authority, if any, required to be made or obtained prior to the Closing by NRx in connection with NRx's consummation of the Transactions by NRx shall have been made or obtained prior to the Closing Date and shall be in full force and effect; and

(d)           No Law, temporary restraining order, preliminary or permanent injunction or other order enacted, entered, promulgated, enforced, or issued by any Governmental Authority or other legal restraint or prohibition by a Governmental Authority shall be pending or in effect seeking to prevent or actually preventing the consummation of the Transactions.

6.2           Conditions to NRx's Performance. The obligation of NRx to complete the Closing of the Transactions is subject to the satisfaction (or written waiver by NRx), on or prior to the Closing Date, of each of the following conditions:

(a)           Relief shall have performed in all material respects all covenants and obligations required by this Agreement to be performed by Relief on or prior to the Closing Date;

(b)           Relief’s representations and warranties set forth in Section 4 shall be true and correct in all material respects (except for such representations and warranties that are qualified by their terms by a reference to "Material Adverse Effect," which representations and warranties as so qualified shall be true and correct in all respects) as of the Closing Date;

(c)           All filings with and consents of any Governmental Authority, if any, required to be made or obtained by Relief prior to the Closing in connection with Relief’s execution and delivery of this Agreement or consummation of the Transactions by Relief shall have been made or obtained prior to the Closing Date and shall be in full force and effect; and

(d)           No Law, temporary restraining order, preliminary or permanent injunction or other order enacted, entered, promulgated, enforced or issued by any Governmental Authority or other legal restraint or prohibition by a Governmental Authority shall be pending or in effect seeking to prevent or actually preventing the consummation of the Transactions.

SECTION 7. Indemnification

7.1           Indemnification by NRx. Subject to the other provisions of this Section 7, following the Closing, NRx shall indemnify, defend (as provided in Section 7.3), and hold harmless Relief, its Affiliates, and each of their respective officers, directors, employees, agents, successors and permitted assigns (each a "Relief Indemnified Party") from and against and in respect of any and all Damages to the extent caused by, related to, or arising, directly or indirectly, from or in connection with any of the following:

(a)           any Excluded Liabilities or Excluded Assets;

(b)           any inaccuracy in or breach of any representation or warranty made by NRx in this Agreement; or

(c)           any breach or nonfulfillment by NRx of any of its covenants, obligations or agreements contained in this Agreement;

7.2           Indemnification by Relief. Subject to the other provisions of this Section 7, following the Closing, Relief shall indemnify, defend (as provided in Section 7.3), and hold harmless NRx, its Affiliates, and each of their respective officers, directors, employees, agents, successors and permitted assigns (each a "NRx Indemnified Party") from and against and in respect of any and all Damages to the extent caused by, related to, or arising, directly or indirectly, from or in connection with any of the following:

(a)           any Assumed Liabilities;

(b)           any inaccuracy in or breach of any representation or warranty made by Relief in this Agreement; or

(c)           any breach or nonfulfillment by Relief of any of its covenants, obligations or agreements contained in this Agreement;

7.3           Limitations. The Party making a claim under this Section is referred to as the “Indemnified Party”, and the party against whom such claims are asserted under this Section is referred to as the “Indemnifying Party”. The indemnification provided for in Section 7.1 and Section 7.2 shall be subject to the following limitations: (a) the Indemnifying Party shall not be liable to the Indemnified Party for indemnification under Section 7.1(b) or Section 7.2(b), as the case may be, until the aggregate amount of all Damages in respect of indemnification exceeds Five Hundred Thousand Dollars ($500,000) (the “Deductible”), in which event the Indemnifying Party shall only be required to pay or be liable for Damages in excess of the Deductible, and (b) the aggregate amount of all Damages for which an Indemnifying Party shall be liable or required to pay pursuant to Section 7.1(b) or Section 7.2(b), as the case may be, shall not exceed Two Million Dollars ($2,000,000) and the aggregate amount of all Damages for which NRx shall be liable or required to pay pursuant to Section 7.1(c) shall not exceed Three Million Dollars ($3,000,000). Notwithstanding the foregoing, if Relief fails to use Commercially Reasonable Efforts to develop, commercialize and market the Product or no Royalty Payments or Milestone Payments are actually paid, NRx shall have no obligation for indemnification hereunder other than under Section 7.1(a). Except for indemnification under Section 7.1(a), which shall not be covered by the limitation in this sentence, NRx's total indemnity obligation to Relief under this Agreement shall not exceed the total amount of Royalty Payments and Milestone Payments actually paid to NRx hereunder. Relief acknowledges and agrees that it has had an opportunity to conduct a thorough investigation and due diligence inquiry on NRx and its Affiliates, and in no event shall NRx or any of its Affiliates have any liability to Relief or any of its Affiliates with respect to the breach of any representation or warranty in this Agreement to the extent Relief or any of its Affiliates knew of such breach as of the Closing Date. Each Indemnified Party shall take, and cause its Affiliates to take, all reasonable steps to mitigate any Damages upon becoming aware of any event or circumstance that would be reasonably expected to, or does, give rise thereto, including incurring costs only to the minimum extent necessary to remedy the breach that gives rise to such Damages.

7.4           Third-Party Claims.

(a)           If any Indemnified Party becomes aware of a Third Party claim (including any action or proceeding commenced or threatened to be commenced by any Third Party) that the Indemnified Party reasonably believes may give rise to the Indemnifying Party’s obligation to indemnify pursuant to this Section 7 (any such claim, a "Third-Party Claim"), the Indemnified Party shall promptly notify the Indemnifying Party in writing of such Third-Party Claim (such notice, the "Claim Notice"). The Claim Notice shall be accompanied by copies of any relevant and material documentation submitted by the Third Party making such Third-Party Claim and shall describe in reasonable detail (to the extent known by the Indemnified Party) the facts constituting the basis for such Third-Party Claim and the amount of the claimed Damages; provided that no delay or failure on the part of the Indemnified Party in delivering a Claim Notice shall relieve the Indemnifying Party from any liability hereunder except and only to the extent the Indemnifying Party shall have been actually and materially prejudiced as a result of such delay or failure.

(b)           Within twenty (20) Business Days after receipt of any Claim Notice, the Indemnifying Party may, upon written notice thereof to the Indemnified Party, assume control of the defense of the Third-Party Claim referred to therein at the Indemnifying Party’s sole cost and expense with counsel reasonably satisfactory to the Indemnified Party. Notwithstanding anything to the contrary contained herein, the Indemnifying Party shall not be entitled to assume or control the investigation, defense or prosecution of such Third-Party Claim if (i) a material portion of the Damages associated with such Third-Party Claim are not reasonably expected to be indemnifiable hereunder, (ii) at the time of assumption or thereafter, the Indemnifying Party fails to conduct the investigation, defense or prosecution actively and diligently, or (iii) such Third-Party Claim seeks non-monetary, equitable or injunctive relief against the Indemnified Party or alleges any violation of Law by the Indemnified Party; and in each such case ((i), (ii) or (iii)), the Indemnified Party may assume control of its defense.

(c)           The Party not controlling the defense of such Third-Party Claim (the "Non-Controlling Party") may participate therein at its own expense; provided, however, that if the Indemnifying Party assumes control of the defense of such Third-Party Claim and the Indemnifying Party and the Indemnified Party have materially conflicting interests or different defenses available with respect to such Third-Party Claim which cause the Indemnified Party to hire its own separate counsel with respect to such proceeding, the reasonable fees and expenses of counsel to the Indemnified Party shall be considered "Damages" for purposes of this Agreement. The Party controlling the defense of such Third-Party Claim (the "Controlling Party") shall keep the Non-Controlling Party advised, in writing, of the status of such Third-Party Claim and the defense thereof and shall consider in good faith recommendations made by the Non-Controlling Party with respect thereto. The Non-Controlling Party shall furnish the Controlling Party with such information as it may have with respect to such Third-Party Claim (including copies of any summons, complaint or other pleading which may have been served on such Party and any written claim, demand, invoice, billing or other document evidencing or asserting the same) and shall otherwise cooperate with and assist the Controlling Party, as reasonably requested by the Controlling Party, in the defense of such Third-Party Claim.

(d)           The Indemnifying Party shall not agree to any settlement of, or the entry of any judgment arising from, any Third-Party Claim without the prior written consent of the Indemnified Party, which shall not be unreasonably withheld or delayed; provided, however, that the consent of the Indemnified Party shall not be required with respect to any such settlement or judgment if (i) such settlement or judgment (A) involves no admission of wrongdoing by the Indemnified Party, and (B) the sole relief provided is monetary Damages, and (ii) the Indemnifying Party agrees in writing to pay or cause to be paid any amounts payable pursuant to such settlement or judgment and such settlement or judgment includes a complete release of the Indemnified Party and its Affiliates, directors, officers, employees and representatives from further liability. Whether or not the Indemnifying Party shall have assumed the defense of a Third-Party Claim, the Indemnified Party shall not admit liability with respect to, or agree to any settlement of or the entry of any judgment arising from, any such Third-Party Claim without the prior written consent of the Indemnifying Party, which shall not be unreasonably withheld or delayed; provided that the consent of the Indemnifying Party shall not be required with respect to any such settlement or judgment if the Indemnified Party agrees in writing to pay or cause to be paid any amounts payable pursuant to such settlement or judgment and that no Indemnified Party is entitled to indemnification under this Agreement in respect of such settlement or judgment. Furthermore, a Party’s consent to any settlement of a Third-Party Claim shall not be used as evidence of the truth of the allegations in any Third-Party Claim or the merits of such Third-Party Claim and the existence of any Third-Party Claim shall not create a presumption of any breach by a Party to this Agreement of any of its representations, warranties or covenants set forth in this Agreement.

7.5           LIMITS ON INDEMNIFICATION. NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR ANY INCIDENTAL, SPECIAL, EXEMPLARY, PUNITIVE OR CONSEQUENTIAL LOSSES, LOSSES BASED UPON LOST REVENUES OR PROFITS, DIMINUTION OF VALUE, MULTIPLE OF EARNINGS, PROFITS OR CASH FLOW OR SIMILAR MEASURES, HOWEVER CAUSED OR ON ANY THEORY OF LIABILITY, THAT ARISE OUT OF OR RELATE TO THIS AGREEMENT OR THE PERFORMANCE OR BREACH HEREOF OR THEREOF OR ANY OTHER TRANSACTION CONTEMPLATED HEREBY, ALL OF WHICH ARE HEREBY EXCLUDED BY AGREEMENT OF THE PARTIES REGARDLESS OF WHETHER OR NOT ANY PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH LOSSES; PROVIDED THAT NOTHING IN THIS SECTION 7.5 SHALL LIMIT OR RESTRICT (A) THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY UNDER THIS SECTION 7 WITH RESPECT TO THIRD-PARTY CLAIMS, (B) EITHER PARTY’S LIABILITY FOR BREACHES OF THE CONFIDENTIALITY OBLIGATIONS IN SECTION 8, or (C) NRX'S LIABILITY FOR BREACH OF SECTION 5.6.

7.6           Reserved.

7.7           Survival and Expiration of Representations, Warranties and Covenants.

(a)           The representations and warranties made by each of NRx and Relief in Section 3 and Section 4, respectively, shall survive the Closing and remain in full force and effect until the date that is eighteen (18) months after the Closing Date (the "Expiration Date"). None of the covenants or other agreements contained in this Agreement shall survive the Closing Date other than those which by their terms contemplate performance after the Closing Date, and each such surviving covenant and agreement shall survive the Closing for the period contemplated by its terms. If Relief or NRx delivers to the other Party, before the Expiration Date, either a Claim Notice or based upon a breach of a representation or warranty in Section 3 or Section 4, then such claim and associated representation and warranty and right to indemnification (including any right to pursue such indemnification hereunder) will not terminate, and shall survive until (but only for purposes of) the resolution and final determination of such claim covered by such Claim Notice.

(b)           Each covenant and agreement in this Agreement, and all associated rights to indemnification (including any right to pursue such indemnification hereunder), will survive the Closing and will continue in full force thereafter, without limitation as to time, until fully performed in accordance with its terms or until the date that is ninety (90) days past the expiration of the applicable statute of limitations period relating to such covenant or agreement. Any claims based on fraud will survive the Closing indefinitely.

7.8           Right of Set off. If a Third Party makes a Third-Party Claim against any Relief Indemnified Party, then, at any time that Relief incurs or otherwise suffers Damages (including reasonable fees and expenses of counsel and other professionals and experts if NRx (as the Indemnifying Party) fails to assume control of the defense of such Third-Party Claim for any reason or if Relief (as the Indemnified Party) assumes control of the defense of such Third-Party Claim pursuant to Section 7.4(b)), Relief may set off the amount of the Damages incurred or otherwise suffered by Relief in connection with such Third-Party Claim against milestone payments or Royalty Payments which has not been paid to NRx in accordance with this Agreement. Neither the exercise of, nor the failure to exercise, such right of set off shall constitute an election of remedies or limit Relief in any manner in the enforcement of any other remedies that may be available to Relief.

7.9           Construction. For purposes of determining whether a breach has occurred in connection with a claim for indemnification under this Section 7, each of the representations and warranties that contains any qualifications as to "materiality" shall be deemed to have been given as though there were no such qualifications.

SECTION 8. Confidentiality

8.1           Confidential Information. Except as expressly provided herein, the Parties agree that the receiving Party of Confidential Information shall not, directly or indirectly, publish or otherwise disclose to any Third Party and shall not use for any purpose at any time any Confidential Information (whether or not such information is or was developed by any of them), except to the extent permitted under this Section 8. The receiving Party shall: (i) use the disclosing Party's Confidential Information solely for the purpose for which it was provided, and (ii) maintain the Confidential Information as confidential and safeguard such Confidential Information and to protect it against disclosure, misuse, loss and theft. The Parties agree that Confidential Information is not deemed to be in the public domain merely because any part of the information is embodied in general disclosures or because individual features, components or combinations are now, or become, known to the public. Notwithstanding the foregoing, Confidential Information shall not include information that, in each case as demonstrated by written documentation:

(a)           was already known to the receiving Party at the time of disclosure, other than under an obligation of confidentiality;

(b)           was available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party;

(c)           became available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving Party in breach of this Agreement;

(d)           was independently developed by the receiving party after the Closing Date; or

(e)           was disclosed to the receiving Party, other than under an obligation of confidentiality, by a Third Party who had no obligation of confidentiality to the disclosing Party or any other Third Party.

8.2           Permitted Disclosures. Notwithstanding Section 8.1, each receiving Party may disclose Confidential Information of the disclosing Party to the extent that such disclosure is:

(a)           made on or behalf of Relief to any Governmental Authority or any Regulatory Authority as required in connection with the filing, application or request for Marketing Approval of the Product; provided, however, that reasonable measures shall be taken to assure confidential treatment of such information to the extent practicable and consistent with applicable Law;

(b)           made in response to a valid order of competent jurisdiction or other supra-national, federal, national, regional, state, provincial and local governmental or regulatory body of competent jurisdiction or, if in the reasonable opinion of the receiving Party's legal counsel, such disclosure is required by applicable Law, including, without limitation, disclosure requirements with the SIX Swiss Exchange (the "SIX") and the United States Securities and Exchange Commission ("SEC"), provided, however, that to the extent practicable and not otherwise prohibited by applicable Law, the receiving Party shall first have given notice to the disclosing Party and given the disclosing Party (i) a reasonable opportunity to quash such order or to obtain a protective order or confidential treatment requiring that the Confidential Information and documents that are subject of such order be held in confidence by such court or agency or, if disclosed, be used only for the purposes for which the order was issued, and (ii) a right to review and comment upon such disclosure, which comments shall be considered in good faith by the receiving Party, and provided further that the Confidential Information disclosed in response to such court or governmental order shall be limited to the information which is legally required to be disclosed in response to such court or governmental order;

(c)           made by or on behalf of Relief as may reasonably be necessary for the purposes of the registration and pursuit of the Transferred IP, provided, however, that reasonable measures shall be taken to assure the confidential treatment of such information, to the extent such protection is available; or

(d)           made in confidence by the receiving party to its or its Affiliates' attorneys, auditors, advisers, consultants, or contractors who have a reasonable need to know.

8.3           Public Announcements. Notwithstanding anything to the contrary herein, except as may be required to comply with the requirements of any applicable Law, including the rules and regulations of the SIX or the SEC or other stock exchange upon which the securities of a Party is listed, from and after the Execution Date, no press release or similar public announcement or communication shall be made or caused to be made by either Party or any of its Affiliates relating to this Agreement or the Transactions without the prior written consent of the other Party (such consent not to be unreasonably withheld, conditioned or delayed); provided that the Parties will issue press releases, in each case that are approved by mutual agreement of the Parties, announcing (a) the execution of this Agreement and (b) the Closing of the Transactions. For clarity, Relief and NRx may issue such press releases, public announcements or communications or make such SEC filings as it determines are reasonably necessary to comply with disclosure requirements of the SIX and the SEC.

8.4           Survival. The receiving Party’s obligations of confidentiality and non-use with respect to any Confidential Information set forth in this Section 8 shall survive termination of this Agreement for a period of seven (7) years thereafter; provided that such obligations with respect to any Confidential Information comprising a Trade Secret of the disclosing Party shall survive and continue for as long as such Confidential Information qualifies as a Trade Secret of the disclosing Party under applicable Law.

SECTION 9. Miscellaneous Provisions

9.1           Force Majeure. Neither Party shall be liable for any nonperformance or delay in performance of its obligations under this Agreement to the extent such failure is attributable to acts or events (including acts of God, war, terrorist activities, conditions or events of nature, industry wide supply shortages, civil disturbances, embargo, work stoppage, power failures, fire, flood, earthquake, epidemic, pandemic (other than COVID-19), unavailability of supplies, materials or transportation, or any applicable Law or decision, order or judgment of any Governmental Authority), and in general any other cause or condition beyond its reasonable control which impair or prevent in whole or in part performance by such Party hereunder; provided that the payment of amounts due and owing hereunder shall not be excused or delayed as a result of any force majeure act or event. If a Party is unable to perform its duties and obligations hereunder as a result of an event of force majeure, as described in the first sentence of this Section 9.1, the affected Party shall, as promptly as reasonably practicable, give notice of the occurrence of such event to the other Party and shall use its Commercially Reasonable Efforts to resume the performance at the earliest reasonably practicable date.

9.2           Amendment. This Agreement may not be modified, amended, altered, or supplemented except upon the execution and delivery of a written agreement executed by an authorized representative of each Party.

9.3           Expenses. Except as set forth in this Agreement, all fees and expenses incurred in connection with this Agreement and the Transactions shall be paid by the Party incurring such expenses.

9.4           Waiver.

(a)           No failure on the part of a Party to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part of a Party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy.

(b)           No Party shall be deemed to have waived any claim arising out of this Agreement, or any power, right, privilege or remedy under this Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of such Party; and any such waiver shall not be applicable or have any effect except in the specific instance in which it is given.

9.5           Entire Agreement. This Agreement, together with the Exhibits and Schedules hereto, the Disclosure Schedule, Updated Disclosure Schedule, Ancillary Agreements and the Settlement Agreement, constitutes the entire agreement between the Parties with respect to the subject matter hereof and supersedes all prior agreements and understandings, both written and oral, between the Parties with respect to such subject matter, including any confidentiality agreement previously in place between the parties which is superseded hereby.

9.6           Applicable Law; Jurisdiction; Waiver of Jury Trial. This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws thereof. In the event of any dispute or controversy arising under or related to this Agreement that is not resolved amicably through good faith discussion, each of the Parties irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the federal or state courts in Manhattan, New York. Each of the Parties waives any defense of inconvenient forum to the maintenance of any action so brought and waives any bond, surety or other security that might be required of any other Party with respect thereto. Each Party hereby waives, to the fullest extent permitted by Law, any right to trial by jury of any claim, demand, action, or cause of action (a) arising under this Agreement or (b) in any way connected with or related or incidental to the dealings of the Parties in respect of this Agreement or the Transactions, in each case, whether now existing or hereafter arising, and whether in contract, tort, equity, or otherwise. Each Party hereby further agrees and consents that any such claim, demand, action, or cause of action shall be decided by court trial without a jury and that the Parties may file a copy of this Agreement with any court as written evidence of the consent of the Parties to the waiver of their right to trial by jury.

9.7           Assignment. Neither this Agreement nor any of the rights or obligations hereunder may be assigned by NRx or Relief without the prior written consent of the Other Party, and any attempted assignment of this Agreement or any such rights or obligations without such consent shall be void and of no effect; provided that (a) either Party may assign this Agreement or any such rights or obligations to an Affiliate without the prior written consent of the other Party, and (b) either Party may assign this Agreement as a whole without the consent of the other Party, to a successor in connection with the acquisition (whether by merger, consolidation, sale or otherwise) of such Party or of that part of such Party’s business to which this Agreement relates. Subject to the foregoing, this Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the Parties hereto and their respective successors and assigns.

9.8           Third Party Beneficiaries. Except for the rights to indemnification provided for in Section 7, nothing in this Agreement, express or implied, is intended to or shall confer upon any Person (other than the Parties) any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.

9.9           Notices. Any notice or other communication required or permitted to be delivered to either Party under this Agreement shall be in writing and shall be deemed properly delivered, given and received (a) upon receipt when delivered by hand, or (b) one Business Day after being sent by courier or express next-day delivery service, provided that in each case the notice or other communication is sent to the address set forth beneath the name of such Party below (or to such other address as such Party shall have specified in a written notice given to the other Party):

If to Relief:

RELIEF THERAPEUTICS Holding SA

Avenue de Sécheron 15

1202 Genève

Switzerland

Attention: Jack Weinstein, Chief Financial Officer

jack.weinstein@relieftherapeutics.com

with a copy to (which shall not constitute notice):

Philip B. Schwartz, Esq.

Akerman LLP

201 East Las Olas Boulevard

Suite 1800

Fort Lauderdale, FL 33301

954-468-2455

philip.schwartz@akerman.com

if to NRx Pharma and NeuroRx:

NRx Pharmaceuticals, Inc.

1201 North Market Street

Suite 111

Wilmington, DE 19801

Attention: Stephen H. Willard, Chief Executive Officer

willard@nrxpharma.com

with copies (which will not constitute notice hereunder) to:

Douglas Boggs, Esq.

DLA Piper (US) LLP

500 8th Street, NW

Washington, DC 20004

202-799-4070

douglas.boggs@us.dlapiper.com

9.10         Severability. If any term or other provision of this Agreement, or any portion thereof, is invalid, illegal or incapable of being enforced by any rule of Law or public policy, all other terms and provisions of this Agreement, or remaining portion thereof, shall nevertheless remain in full force and effect so long as the economic or legal substance of the Transactions is not affected in any manner materially adverse to any Party hereto. Upon such determination that any such term or other provision, or any portion thereof, is invalid, illegal or incapable of being enforced, the Parties shall negotiate in good faith to modify this Agreement so as to affect the original intent of the Parties as closely as possible in an acceptable manner to the end that the Transactions are consummated to the fullest extent possible.

9.11         Specific Performance; Non-Exclusive Remedies. Each Party agrees that this Agreement is intended to be legally binding and specifically enforceable pursuant to its terms and that Relief and NRx would be irreparably harmed if any of the provisions of this Agreement were not performed in accordance with their specific terms and that monetary damages would not provide adequate remedy in such event. Accordingly, in addition to any other remedy to which a non-breaching Party may be entitled at Law, a non-breaching Party shall be entitled to seek injunctive relief to prevent breaches of this Agreement and to specifically enforce the terms and provisions hereof, in each case without posting a bond or undertaking, this being in addition to any other remedy to which they are entitled at law or in equity. Each of the Parties agrees that it will not oppose the granting of an injunction, specific performance, and other equitable relief when expressly available pursuant to the terms of this Agreement on the basis that the other Party has an adequate remedy at law or that an award of specific performance is not an appropriate remedy for any reason at law or equity. The rights and remedies provided in this Agreement are cumulative and do not exclude any other right or remedy provided by applicable Law or otherwise available.

9.12         Standstill Agreement. Unless approved in advance in writing by the board of directors of the other Party, for the five years following the Closing Date, neither NRx nor Relief, nor any of their respective officers, directors or Affiliates, will (a) acquire collectively an interest in the other Party exceeding 5% of the other Party's outstanding common stock (in the case of NRx) or ordinary shares (in the case of Relief), on a fully diluted basis, (b) take any action that would reasonably be expected to effect such a transaction in the future, or (c) encourage, instigate or assist any third party to take an action to acquire such interest.

9.13         Construction.

(a)           For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine genders.

(b)           The Parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or interpretation of this Agreement.

(c)           As used in this Agreement, the words "include" and "including," and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words "without limitation."

(d)           the term "or" will be interpreted in the inclusive sense commonly associated with the term "and/or."

(e)           Except as otherwise indicated, all references in this Agreement to "Sections," "Exhibits" and "Schedules" are intended to refer to Sections of this Agreement and Exhibits and Schedules to this Agreement.

(f)            The bold-faced headings contained in this Agreement are for convenience of reference only, shall not be deemed to be a part of this Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement.

(g)           As used in this Agreement, the word "day" will mean calendar day unless Business Day is specified.

9.14         Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Each of the signatories to this Agreement may execute this Agreement in Adobe™ Portable Document Format (PDF) sent by electronic mail or by other electronic means. PDF or other electronic signatures of authorized signatories of the Parties will be deemed to be original signatures, will be valid and binding upon the Parties, and, upon delivery, will constitute due execution of this Agreement.

[Signature Page Follows]

In Witness Whereof, the Parties have caused this Asset Purchase Agreement to be executed as of the Execution Date.

	NRx Pharmaceuticals, Inc.


	By:	/s/ Stephen Willard
	Name:  Stephen Willard
	Title: Chief Executive Officer


	NeuroRx, Inc.


	By:	/s/ Stephen Willard
	Name: Stephen Willard
	Title: CEO


	RELIEF THERAPEUTICS Holding SA


	By:	/s/ Jeremy Meinen
	Name: Jeremy Meinen
	Title: VP Finance, CAO


	RELIEF THERAPEUTICS INTERNATIONAL SA


	By:	/s/ Jeremy Meinen
	Name: Jeremy Meinen
	Title: VP Finance, CAO

Exhibit A

Form of Intellectual Property Assignment Agreement

[Redacted]

Exhibit B

Form of Assignment and Assumption Agreement

[Redacted]

Exhibit C

Form of Bill of Sale

[Redacted]

Exhibit D

Settlement Agreement

Schedule 1.13
Compound

Schedule 1.67
Transferred Contracts

Company / Vendor	Service	Dated

Schedule 1.68
Transferred IP

Schedule 1.69

Inventory of Product and Compound

Schedule 2.5(b)

Closing Deliveries

Schedule 4.5

Relief Litigation Regarding the Product

[Redacted]

EX-31.1 4 tm2314196d1_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER

PURSUANT TO RULE 13a-14(a) AND 15d-14(a),

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Stephen H. Willard, Chief Executive Officer of NRx Pharmaceuticals, Inc., certify that:

1.	I have reviewed this Amendment No. 1 to the Annual Report on Form 10-K/A of NRx Pharmaceuticals, Inc. (the “Registrant”);

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Amendment No. 1 to the Annual Report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the Registrant as of, and for, the periods presented in this Amendment No. 1 to the Annual Report;

The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant is made known to us by others within those entities, particularly during the period in which this Amendment No. 1 to the Annual Report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

5.	The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

Date: May 1, 2023	/s/ Stephen H. Willard
	Stephen H. Willard
	Chief Executive Officer (Principal Executive Officer)

EX-31.2 5 tm2314196d1_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER

PURSUANT TO RULE 13a-14(a) AND 15d-14(a),

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Seth Van Voorhees, Chief Financial Officer of NRx Pharmaceuticals, Inc., certify that:

1.	I have reviewed this Amendment No. 1 to the Annual Report on Form 10-K/A of NRx Pharmaceuticals, Inc. (the “Registrant”);

5.	The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing equivalent functions):

Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

Date: May 1, 2023	/s/ Seth Van Voorhees
	Seth Van Voorhees
	Chief Financial Officer (Principal Financial Officer)

EX-101.SCH 6 nrxp-20221231.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 7 nrxp-20221231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 nrxp-20221231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Common Stock [Member] Warrant [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] ICFR Auditor Attestation Flag Auditor Firm ID Auditor Name Auditor Location EX-101.PRE 9 nrxp-20221231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 R1.htm IDEA: XBRL DOCUMENT

Cover - USD ($) $ in Millions	12 Months Ended
Cover - USD ($) $ in Millions	Dec. 31, 2022	Apr. 27, 2023	Jun. 30, 2022
Document Type	10-K/A
Amendment Flag	true
Amendment Description	NRx Pharmaceuticals, Inc. (the "Company") is filing this Amendment No. 1 (this "Form 10-K/A") to its Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the Securities and Exchange Commission (the "SEC") on March 31, 2023 (the "Form 10-K"), for the purpose of including the information required by Part III and Exhibits required by Part IV of Form 10-K. As required by Rule 12b-15, in connection with this Form 10-K/A, the Company's Principal Executive Officer and Principal Financial Officer are providing Rule 13a-14(a) certifications included herein. Because no financial statements have been included in this Form 10-K/A and this Form 10-K/A does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications have been omitted. Because no financial statements are contained within this Form 10-K/A, the Company is not including certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Except as explicitly set forth herein, this Form 10-K/A does not purport to modify or update the disclosures in, or exhibits to original Form 10-K, or to update the original Form 10-K to reflect events occurring after the date of such filing.
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-38302
Entity Registrant Name	NRX PHARMACEUTICALS, INC.
Entity Central Index Key	0001719406
Entity Tax Identification Number	82-2844431
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1201 Orange Street
Entity Address, Address Line Two	Suite 600
Entity Address, City or Town	Wilmington
Entity Address, State or Province	DE
Entity Address, Postal Zip Code	19801
City Area Code	484
Local Phone Number	254-6134
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 40,584,788.4
Entity Common Stock, Shares Outstanding		71,557,580
ICFR Auditor Attestation Flag	false
Auditor Firm ID	185
Auditor Name	KPMG LLP
Auditor Location	Short Hills, new Jersey
Common Stock [Member]
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	NRXP
Security Exchange Name	NASDAQ
Warrant [Member]
Title of 12(b) Security	Warrants to purchase one share of Common Stock
Trading Symbol	NRXPW
Security Exchange Name	NASDAQ

XML 11 tm2314196d1_10ka_htm.xml IDEA: XBRL DOCUMENT 0001719406 2022-01-01 2022-12-31 0001719406 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001719406 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001719406 2022-06-30 0001719406 2023-04-27 iso4217:USD shares iso4217:USD shares 0001719406 true --12-31 2022 FY NRx Pharmaceuticals, Inc. (the "Company") is filing this Amendment No. 1 (this "Form 10-K/A") to its Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the Securities and Exchange Commission (the "SEC") on March 31, 2023 (the "Form 10-K"), for the purpose of including the information required by Part III and Exhibits required by Part IV of Form 10-K. As required by Rule 12b-15, in connection with this Form 10-K/A, the Company's Principal Executive Officer and Principal Financial Officer are providing Rule 13a-14(a) certifications included herein. Because no financial statements have been included in this Form 10-K/A and this Form 10-K/A does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications have been omitted. Because no financial statements are contained within this Form 10-K/A, the Company is not including certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Except as explicitly set forth herein, this Form 10-K/A does not purport to modify or update the disclosures in, or exhibits to original Form 10-K, or to update the original Form 10-K to reflect events occurring after the date of such filing. 10-K/A true 2022-12-31 false 001-38302 NRX PHARMACEUTICALS, INC. DE 82-2844431 1201 Orange Street Suite 600 Wilmington DE 19801 484 254-6134 Common Stock, par value $0.001 per share NRXP NASDAQ Warrants to purchase one share of Common Stock NRXPW NASDAQ No No Yes Yes Non-accelerated Filer true false false false 40584788400000 71557580 185 KPMG LLP Short Hills, new Jersey EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 5 38 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://nrxpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate - tm2314196d1_10ka.htm 25 tm2314196d1_10ka.htm nrxp-20221231.xsd nrxp-20221231_def.xml nrxp-20221231_lab.xml nrxp-20221231_pre.xml tm2314196d1_ex10-54.htm tm2314196d1_ex10-55.htm tm2314196d1_ex31-1.htm tm2314196d1_ex31-2.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 18 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2314196d1_10ka.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 41 }, "contextCount": 5, "dts": { "definitionLink": { "local": [ "nrxp-20221231_def.xml" ] }, "inline": { "local": [ "tm2314196d1_10ka.htm" ] }, "labelLink": { "local": [ "nrxp-20221231_lab.xml" ] }, "presentationLink": { "local": [ "nrxp-20221231_pre.xml" ] }, "schema": { "local": [ "nrxp-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 69, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 6, "total": 6 }, "keyCustom": 0, "keyStandard": 38, "memberCustom": 0, "memberStandard": 2, "nsprefix": "nrxp", "nsuri": "http://nrxpharma.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2314196d1_10ka.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://nrxpharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2314196d1_10ka.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nrxpharma.com/role/Cover" ], "xbrltype": "domainItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 19 0001104659-23-054557-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-054557-xbrl.zip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end